<article title='N%2CN-Dimethyltryptamine'><paragraph><template><target>DISPLAYTITLE:''N'',''N''-Dimethyltryptamine</target></template><template><target>Drug</target><arg name="Watchedfields"><space/>changed
</arg><arg name="drug_name"><space/>''N'',''N''-Dimethyltryptamine
</arg><arg name="verifiedrevid"><space/>623685269
</arg><arg name="IUPAC_name"><space/>2-(1''H''-Indol-3-yl)-''N'',''N''-dimethylethanamine
</arg><arg name="image"><space/>DMT.svg
</arg><arg name="width"><space/>200
</arg><arg name="image2"><space/>Dimethyltryptamine_27feb.gif
</arg><arg name="width2"><space/>200

<space/></arg><arg name="legal_AU"><space/>S9
</arg><arg name="legal_CA"><space/>Schedule III
</arg><arg name="legal_UK"><space/>CD Lic
</arg><arg name="legal_US"><space/>Schedule I
</arg><arg name="legal_DE"><space/>Anlage I
</arg><arg name="routes_of_administration"><space/>[[Mouth|Oral]] (with an [[monoamine oxidase inhibitor|MAOI]]), [[insufflation (medicine)|insufflated]], [[Rectal (medicine)|rectal]], [[Vaporization|vaporized]], [[Intramuscular injection|IM]], [[intravenous injection|IV]]

<space/></arg><arg name="CAS_number_Ref"><space/>{{cascite|correct|??}}
</arg><arg name="CAS_number"><space/>61-50-7
</arg><arg name="ATC_prefix"><space/>none
</arg><arg name="DrugBank_Ref"><space/>{{drugbankcite|correct|drugbank}}
</arg><arg name="DrugBank"><space/>DB01488
</arg><arg name="UNII_Ref"><space/>{{fdacite|correct|FDA}}
</arg><arg name="UNII"><space/>WUB601BHAA
</arg><arg name="ChEBI_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEBI"><space/>28969
</arg><arg name="PubChem"><space/>6089
</arg><arg name="IUPHAR_ligand"><space/>141
</arg><arg name="ChemSpiderID_Ref"><space/>{{chemspidercite|correct|chemspider}}
</arg><arg name="ChemSpiderID"><space/>5864
</arg><arg name="KEGG_Ref"><space/>{{keggcite|correct|kegg}}
</arg><arg name="KEGG"><space/>C08302
</arg><arg name="ChEMBL_Ref"><space/>{{ebicite|correct|EBI}}
</arg><arg name="ChEMBL"><space/>12420

<space/></arg><arg name="C">12<space/></arg><arg name="H">16<space/></arg><arg name="N">2
</arg><arg name="molecular_weight"><space/>188.269 g/mol
</arg><arg name="smiles"><space/>CN(CCC1</arg><arg name="InChI"><space/>1/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3
</arg><arg name="StdInChI_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChI"><space/>1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3
</arg><arg name="StdInChIKey_Ref"><space/>{{stdinchicite|correct|chemspider}}
</arg><arg name="StdInChIKey"><space/>DMULVCHRPCFFGV-UHFFFAOYSA-N
</arg><arg name="density"><space/>1.099
</arg><arg name="melting_point"><space/>40
</arg><arg name="boiling_point"><space/>160
</arg><arg name="boiling_notes"><space/><br/>@ {{convert|0.6|Torr|Pa|abbr</arg></template><bold><italics>N</italics>,<italics>N</italics>-Dimethyltryptamine</bold><space/>(<bold>DMT</bold><space/>or<space/><bold><italics>N</italics>,<italics>N</italics>-DMT</bold>) is a<space/><link><target>Psychedelic drug</target><part>psychedelic compound</part></link><space/>of the<space/><link><target>tryptamine</target></link><space/>family. It is a<space/><link><target>structural analog</target></link><space/>of<space/><link><target>serotonin</target></link><space/>and<space/><link><target>melatonin</target></link><space/>and a<space/><link><target>functional analog</target></link><space/>of other psychedelic tryptamines such as<space/><link><target>4-AcO-DMT</target></link>,<space/><link><target>5-MeO-DMT</target></link>,<space/><link><target>5-HO-DMT</target></link>,<space/><link><target>psilocybin</target></link><space/>(4-PO-DMT), and<space/><link><target>psilocin</target></link><space/>(4-HO-DMT).</paragraph><paragraph>It is consumed by indigenous<space/><link><target>Amazonian Indians#Amazon</target><part>Amazonian Amerindian</part></link><space/>cultures through the consumption of<space/><link><target>ayahuasca</target></link><space/>for divinatory and healing purposes.<extension extension_name='ref' name="pmid6587171"><template><target>cite journal</target><arg name="last1">McKenna<space/></arg><arg name="first1">Dennis J.<space/></arg><arg name="last2">Towers<space/></arg><arg name="first2">G.H.N.<space/></arg><arg name="last3">Abbott<space/></arg><arg name="first3">F.<space/></arg><arg name="title">Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and ''β''-carboline constituents of ''ayahuasca''<space/></arg><arg name="journal">Journal of Ethnopharmacology<space/></arg><arg name="volume">10<space/></arg><arg name="issue">2<space/></arg><arg name="pages">195–223<space/></arg><arg name="date">April 1984<space/></arg><arg name="pmid">6587171<space/></arg><arg name="issn">0378-8741<space/></arg><arg name="doi">10.1016/0378-8741(84)90003-5</arg></template></extension></paragraph><heading level='2'>History</heading><paragraph>DMT was first synthesized in 1931 by Canadian chemist Richard Helmuth Fredrick Manske (19011977).<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Manske R.H.F.<space/></arg><arg name="title">A synthesis of the methyltryptamines and some derivatives<space/></arg><arg name="journal">Canadian Journal of Research<space/></arg><arg name="year">1931<space/></arg><arg name="volume">5<space/></arg><arg name="issue">5<space/></arg><arg name="pages">592–600<space/></arg><arg name="url">http://rparticle.web-p.cisti.nrc.ca/rparticle/AbstractTemplateServlet?calyLang</arg><arg name="doi">10.1139/cjr31-097</arg></template></extension><extension extension_name='ref' name="bdmxab"><template><target>cite journal</target><arg name="author">Bigwood J., Ott J.<space/></arg><arg name="date">November 1977<space/></arg><arg name="title">DMT: the fifteen minute trip<space/></arg><arg name="journal">Head<space/></arg><arg name="volume">2<space/></arg><arg name="issue">4<space/></arg><arg name="pages">56–61<space/></arg><arg name="url">http://jeremybigwood.net/JBsPUBS/DMT/<space/></arg><arg name="accessdate">2010-11-28<space/></arg><arg name="archiveurl">http://web.archive.org/web/20060127003553/http://jeremybigwood.net/JBsPUBS/DMT/<space/></arg><arg name="archivedate">2006-01-27</arg></template></extension><space/>In general, its discovery as a natural product is credited to Brazilian chemist and<space/><link><target>Microbiology</target><part>microbiologist</part></link><space/>Oswaldo Gonalves de Lima (19081989) who, in 1946, isolated an alkaloid he named<space/><italics>nigerina</italics><space/>(nigerine) from the root bark of<space/><italics>jurema preta</italics>, that is,<space/><italics><link><target>Mimosa tenuiflora</target></link></italics>.<extension extension_name='ref' name="bdmxab"></extension><extension extension_name='ref' name="ott1996"><template><target>cite book</target><arg name="title">Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History<space/></arg><arg name="last">Ott<space/></arg><arg name="first">Jonathan<space/></arg><arg name="authorlink">Jonathan Ott<space/></arg><arg name="edition">2nd, densified<space/></arg><arg name="year">1996<space/></arg><arg name="publisher">Natural Products<space/></arg><arg name="location">Kennewick, WA<space/></arg><arg name="isbn">978-0-9614234-9-0</arg></template></extension><extension extension_name='ref' name="strassman"><template><target>cite book</target><arg name="title">DMT: The Spirit Molecule. A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences<space/></arg><arg name="last">Strassman<space/></arg><arg name="first">Rick J.<space/></arg><arg name="authorlink">Rick Strassman<space/></arg><arg name="year">2001<space/></arg><arg name="publisher">Park Street<space/></arg><arg name="location">Rochester, VT<space/></arg><arg name="isbn">978-0-89281-927-0</arg></template><space/>(<template><target>cite web</target><arg name="url">http://rickstrassman.com/index.php?option</arg><arg name="title">Chapter summaries<space/></arg><arg name="accessdate">27 February 2012</arg></template>)</extension><space/>However, in a careful review of the case<space/><link><target>Jonathan Ott</target></link><space/>shows that the<space/><link><target>empirical formula</target></link><space/>for nigerine determined by Gonalves de Lima, which notably contains an atom of oxygen, can match only a partial, &quot;impure&quot; or &quot;contaminated&quot; form of DMT.<extension extension_name='ref' name="ott1998"><template><target>cite book</target><arg name="last1">Ott<space/></arg><arg name="first1">Jonathan<space/></arg><arg name="authorlink1">Jonathan Ott<space/></arg><arg name="editor1-first">C.<space/></arg><arg name="editor1-last">Müller-Ebeling<space/></arg><arg name="title">Special: Psychoactivity<space/></arg><arg name="series">Yearbook for Ethnomedicine and the Study of Consciousness<space/></arg><arg name="volume">6/7 (1997/1998)<space/></arg><arg name="year">1998<space/></arg><arg name="publisher">VWB<space/></arg><arg name="location">Berlin<space/></arg><arg name="isbn">3-86135-033-5<space/></arg><arg name="pages"><space/></arg><arg name="chapter">Pharmahuasca, anahuasca and vinho da jurema: human pharmacology of oral DMT plus harmine<space/></arg><arg name="chapterurl">https://www.erowid.org/references/texts/show/7105docid6446</arg></template></extension><space/>It was only in 1959, when Gonalves de Lima provided American chemists a sample of<space/><italics>Mimosa tenuiflora</italics><space/>roots, that DMT was unequivocally identified in this plant material.<extension extension_name='ref' name="ott1998"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Pachter I.J., Zacharias D.E., Ribeiro O.<space/></arg><arg name="title">Indole alkaloids of ''Acer saccharinum'' (the silver maple), ''Dictyoloma incanescens'', ''Piptadenia colubrina'', and ''Mimosa hostilis''<space/></arg><arg name="journal">Journal of Organic Chemistry<space/></arg><arg name="date">September 1959<space/></arg><arg name="volume">24<space/></arg><arg name="issue">9<space/></arg><arg name="pages">1285–87<space/></arg><arg name="doi">10.1021/jo01091a032</arg></template></extension><space/>Less ambiguous is the case of isolation and formal identification of DMT in 1955 in seeds and pods of<space/><italics><link><target>Anadenanthera peregrina</target></link></italics><space/>by a team of American chemists led by Evan Horning (19161993).<extension extension_name='ref' name="ott1998"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Fish M.S., Johnson N.M., Horning E.C.<space/></arg><arg name="date">November 1955<space/></arg><arg name="title">Piptadenia alkaloids. Indole bases of ''P. peregrina'' (L.) Benth. and related species<space/></arg><arg name="journal">Journal of the American Chemical Society<space/></arg><arg name="volume">72<space/></arg><arg name="issue">22<space/></arg><arg name="pages">5892–95<space/></arg><arg name="url"><space/></arg><arg name="doi">10.1021/ja01627a034</arg></template></extension><space/>Since 1955, DMT has been<space/><link><target>#Endogenous DMT</target><part>found in a host of organisms</part></link>: in at least fifty plant species belonging to ten<space/><link><target>Family (biology)</target><part>families</part></link>,<extension extension_name='ref' name="ott1994"><template><target>cite book</target><arg name="title">Ayahuasca Analogues: Pangæan Entheogens<space/></arg><arg name="last">Ott<space/></arg><arg name="first">Jonathan<space/></arg><arg name="authorlink">Jonathan Ott<space/></arg><arg name="year">1994<space/></arg><arg name="publisher">Natural Products<space/></arg><arg name="location">[[Kennewick, WA]], USA<space/></arg><arg name="edition">1st<space/></arg><arg name="isbn">978-0-9614234-5-2<space/></arg><arg name="oclc">32895480<space/></arg><arg name="pages">81–3</arg></template></extension><space/>and in at least four animal species, including one<space/><link><target>gorgonian</target></link><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Cimino G., De Stefano S.<space/></arg><arg name="year">1978<space/></arg><arg name="title">Chemistry of Mediterranean gorgonians: simple indole derivatives from ''Paramuricea chamaeleon''<space/></arg><arg name="journal">Comparative Biochemistry and Physiology Part C: Comparative Pharmacology<space/></arg><arg name="volume">61<space/></arg><arg name="issue">2<space/></arg><arg name="pages">361–2<space/></arg><arg name="doi">10.1016/0306-4492(78)90070-9</arg></template></extension><space/>and three mammalian species.</paragraph><paragraph>Another historical milestone is the discovery of DMT in plants frequently used by Amazonian natives as additive to the vine<space/><italics><link><target>Banisteriopsis caapi</target></link></italics><space/>to make<space/><link><target>ayahuasca</target></link><space/>decoctions. In 1957, American chemists Francis Hochstein and Anita Paradies identified DMT in an &quot;aqueous extract&quot; of leaves of a plant they named<space/><italics>Prestonia amazonicum</italics><space/>(<italics>sic</italics>) and described as &quot;commonly mixed&quot; with<space/><italics>B. caapi</italics>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Hochstein F.A., Paradies A.M.<space/></arg><arg name="year">1957<space/></arg><arg name="title">Alkaloids of ''Banisteria caapi'' and ''Prestonia amazonicum''<space/></arg><arg name="journal">Journal of the American Chemical Society<space/></arg><arg name="volume">79<space/></arg><arg name="issue">21<space/></arg><arg name="pages">5735–36<space/></arg><arg name="doi">10.1021/ja01578a041<space/></arg><arg name="url">http://pubs.acs.org/doi/abs/10.1021/ja01578a041</arg></template></extension><space/>The lack of a proper botanical identification of<space/><italics><link><target>Prestonia amazonica</target></link></italics><space/>in this study led American<space/><link><target>ethnobotany</target><part>ethnobotanist</part></link><space/><link><target>Richard Evans Schultes</target></link><space/>(19152001) and other scientists to raise serious doubts about the claimed plant identity.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Schultes R.E., Raffauf R.F.<space/></arg><arg name="year">1960<space/></arg><arg name="title">''Prestonia'': An Amazon narcotic or not?<space/></arg><arg name="journal">Botanical Museum Leaflets, Harvard University<space/></arg><arg name="volume">19<space/></arg><arg name="issue">5<space/></arg><arg name="pages">109–122<space/></arg><arg name="issn">0006-8098<space/></arg><arg name="url">http://www.biodiversitylibrary.org/item/31906#page/126/mode/1up<space/></arg><arg name="accessdate"><space/></arg></template></extension><extension extension_name='ref' name="pmid14337385"><template><target>cite journal</target><arg name="author">Poisson J.<space/></arg><arg name="title">Note sur le "Natem", boisson toxique péruvienne et ses alcaloïdes<space/></arg><arg name="trans_title">Note on "Natem", a toxic Peruvian beverage, and its alkaloids<space/></arg><arg name="language">French<space/></arg><arg name="journal">Annales Pharmaceutiques Françaises<space/></arg><arg name="volume">23<space/></arg><arg name="issue"><space/></arg><arg name="pages">241–4<space/></arg><arg name="date">April 1965<space/></arg><arg name="pmid">14337385<space/></arg><arg name="issn">0003-4509</arg></template></extension><space/>Better evidence was produced in 1965 by French pharmacologist Jacques Poisson, who isolated DMT as a sole alkaloid from leaves, provided and used by<space/><link><target>Aguaruna</target></link><space/>Indians, identified as having come from the vine<space/><italics><link><target>Diplopterys cabrerana</target></link></italics><space/>(then known as<space/><italics>Banisteriopsis rusbyana</italics>).<extension extension_name='ref' name="pmid14337385"></extension><space/>Published in 1970, the first identification of DMT in the plant<space/><italics><link><target>Psychotria viridis</target></link></italics>,<extension extension_name='ref' name="ott1996"></extension><space/>another common additive of ayahuasca, was made by a team of American researchers led by pharmacologist Ara der Marderosian.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Der Marderosian A.H., Kensinger K.M., Chao J.-M., Goldstein F.J.<space/></arg><arg name="year">1970<space/></arg><arg name="title">The use and hallucinatory principles of a psychoactive beverage of the Cashinahua tribe (Amazon basin)<space/></arg><arg name="journal">Drug Dependence<space/></arg><arg name="volume">5<space/></arg><arg name="issue"><space/></arg><arg name="pages">7–14<space/></arg><arg name="issn">0070-7368<space/></arg><arg name="oclc">1566975</arg></template></extension><space/>Not only did they detect DMT in leaves of<space/><italics>P. viridis</italics><space/>obtained from Cashinahua Indians, but they also were the first to identify it in a sample of an ayahuasca decoction, prepared by the same Indians.<extension extension_name='ref' name="ott1996"></extension></paragraph><heading level='2'>Biosynthesis</heading><paragraph><link><target>Image:DMT biosynthetic pathway.png</target><part>thumb</part><part>left</part><part>Biosynthetic pathway for ''N'',''N''-dimethyltryptamine</part></link>Dimethyltryptamine is an<space/><link><target>indole alkaloid</target></link><space/>derived from the<space/><link><target>shikimate</target></link><space/>pathway. Its<space/><link><target>biosynthesis</target></link><space/>is relatively simple and summarized in the picture to the left. In plants, the parent amino acid<space/><link><target>L-tryptophan</target></link><space/>is produced endogenously where in animals<space/><link><target>L-tryptophan</target></link><space/>is an<space/><link><target>essential amino acid</target></link><space/>coming from diet. No matter the source of<space/><link><target>L-tryptophan</target></link>, the biosynthesis begins with its<space/><link><target>decarboxylation</target></link><space/>by an<space/><link><target>aromatic amino acid decarboxylase</target></link><space/>(AADC)<space/><link><target>enzymes</target><part>enzyme</part></link><space/>(step 1). The resulting decarboxylated tryptophan<space/><link><target>Analog (chemistry)</target><part>analog</part></link><space/>is<space/><link><target>tryptamine</target></link>. Tryptamine then undergoes a<space/><link><target>transmethylation</target></link><space/>(step 2): the enzyme<space/><link><target>tryptamine-N-methyltransferase</target><part>indolethylamine-N-methyltransferase</part></link><space/>(INMT)<space/><link><target>Catalysis</target><part>catalyzes</part></link><space/>the transfer of a<space/><link><target>methyl group</target></link><space/>from<space/><link><target>Cofactor (biochemistry)</target><part>cofactor</part></link><space/><link><target>S-adenosyl-methionine</target></link><space/>(SAM), via<space/><link><target>nucleophilic</target></link><space/>attack, to tryptamine. This reaction transforms SAM into<space/><link><target>S-adenosylhomocysteine</target></link><space/>(SAH), and gives the intermediate product<space/><link><target>N-methyltryptamine</target><part>''N''-methyltryptamine</part></link><space/>(NMT).<extension extension_name='ref' name="pmid13685339"><template><target>cite journal</target><arg name="author">Axelrod J.<space/></arg><arg name="title">Enzymatic formation of psychotomimetic metabolites from normally occurring compounds<space/></arg><arg name="journal">Science<space/></arg><arg name="volume">134<space/></arg><arg name="issue"><space/>3475</arg><arg name="page">343<space/></arg><arg name="date">August 1961<space/></arg><arg name="pmid">13685339<space/></arg><arg name="doi">10.1126/science.134.3475.343<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid779022"><template><target>cite journal</target><arg name="author">Rosengarten H., Friedhoff A.J.<space/></arg><arg name="title">A review of recent studies of the biosynthesis and excretion of hallucinogens formed by methylation of neurotransmitters or related substances<space/></arg><arg name="journal">Schizophrenia Bulletin<space/></arg><arg name="volume">2<space/></arg><arg name="issue">1<space/></arg><arg name="pages">90–105<space/></arg><arg name="year">1976<space/></arg><arg name="pmid">779022<space/></arg><arg name="doi">10.1093/schbul/2.1.90<space/></arg><arg name="url">http://schizophreniabulletin.oxfordjournals.org/content/2/1/90.full.pdf<space/></arg><arg name="format"><space/>PDF</arg></template></extension><space/>NMT is in turn transmethylated by the same process (step 3) to form the end product<space/><italics>N</italics>,<italics>N</italics>-dimethyltryptamine. Tryptamine transmethylation is regulated by two products of the reaction: SAH,<extension extension_name='ref' name="pmid6792104"><template><target>cite journal</target><arg name="author">Barker S.A., Monti J.A., Christian S.T.<space/></arg><arg name="title">''N, N''-dimethyltryptamine: an endogenous hallucinogen<space/></arg><arg name="journal">International Review of Neurobiology<space/></arg><arg name="volume">22<space/></arg><arg name="issue"><space/></arg><arg name="pages">83–110<space/></arg><arg name="year">1981<space/></arg><arg name="pmid">6792104<space/></arg><arg name="doi">10.1016/S0074-7742(08)60291-3<space/></arg><arg name="series">International Review of Neurobiology<space/></arg><arg name="isbn">978-0-12-366822-6</arg></template></extension><extension extension_name='ref' name="pmid4756800"><template><target>cite journal</target><arg name="author">Lin R.L., Narasimhachari N., Himwich H.E.<space/></arg><arg name="title">Inhibition of indolethylamine-N-methyltransferase by S-adenosylhomocysteine<space/></arg><arg name="journal">Biochemical and Biophysical Research Communications<space/></arg><arg name="volume">54<space/></arg><arg name="issue">2<space/></arg><arg name="pages">751–9<space/></arg><arg name="date">September 1973<space/></arg><arg name="pmid">4756800<space/></arg><arg name="doi">10.1016/0006-291X(73)91487-3<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid9852119"><template><target>cite journal</target><arg name="author">Thompson M.A., Weinshilboum R.M.<space/></arg><arg name="title">Rabbit lung indolethylamine ''N''-methyltransferase. cDNA and gene cloning and characterization<space/></arg><arg name="journal">Journal of Biological Chemistry<space/></arg><arg name="volume">273<space/></arg><arg name="issue">51<space/></arg><arg name="pages">34502–10<space/></arg><arg name="date">December 1998<space/></arg><arg name="pmid">9852119<space/></arg><arg name="doi">10.1074/jbc.273.51.34502<space/></arg><arg name="url">http://www.jbc.org/content/273/51/34502.long<space/></arg><arg name="accessdate">2010-11-09</arg></template></extension><space/>and DMT<extension extension_name='ref' name="pmid6792104"></extension><extension extension_name='ref' name="pmid9852119"></extension><space/>were shown<space/><italics>ex vivo</italics><space/>to be among the most potent inhibitors of rabbit INMT activity.</paragraph><paragraph>This transmethylation mechanism has been repeatedly and consistently proven by<space/><link><target>Isotope labeling</target><part>radiolabeling</part></link><space/>of SAM methyl group with<space/><link><target>carbon-14</target></link><space/>(<xhtml:sup>14</xhtml:sup>C-CH<xhtml:sub>3</xhtml:sub>)SAM).<extension extension_name='ref' name="pmid13685339"></extension><extension extension_name='ref' name="pmid6792104"></extension><extension extension_name='ref' name="pmid9852119"></extension><extension extension_name='ref' name="pmid14361"><template><target>cite journal</target><arg name="author">Mandel L.R., Prasad R., Lopez-Ramos B., Walker R.W.<space/></arg><arg name="title">The biosynthesis of dimethyltryptamine in vivo<space/></arg><arg name="journal">Research Communications in Chemical Pathology and Pharmacology<space/></arg><arg name="volume">16<space/></arg><arg name="issue">1<space/></arg><arg name="pages">47–58<space/></arg><arg name="date">January 1977<space/></arg><arg name="pmid">14361</arg></template></extension><extension extension_name='ref' name="pmid10552930"><template><target>cite journal</target><arg name="author">Thompson M.A., Moon E., Kim U.J., Xu J., Siciliano M.J., Weinshilboum R.M.<space/></arg><arg name="title">Human indolethylamine ''N''-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization<space/></arg><arg name="journal">Genomics<space/></arg><arg name="volume">61<space/></arg><arg name="issue">3<space/></arg><arg name="pages">285–97<space/></arg><arg name="date">November 1999<space/></arg><arg name="pmid">10552930<space/></arg><arg name="doi">10.1006/geno.1999.5960<space/></arg><arg name="url">http://crfdl.org:1111/xmlui/bitstream/handle/123456789/307/Thompson99humanINMT.pdf?sequence</arg><arg name="format">PDF</arg></template></extension></paragraph><heading level='3'>Evidence in mammals</heading><paragraph>Published in<space/><italics><link><target>Science (journal)</target><part>Science</part></link></italics><space/>in 1961,<space/><link><target>Julius Axelrod</target></link><space/>found an<space/><italics>N</italics>-<link><target>methyltransferase</target></link><space/>enzyme capable of mediating biotransformation of tryptamine into DMT in a rabbit's lung.<extension extension_name='ref' name="pmid13685339"></extension><space/>This finding initiated a still ongoing scientific interest in endogenous DMT production in humans and other mammals.<extension extension_name='ref' name="pmid779022"></extension><extension extension_name='ref' name="pmid16095048"><template><target>cite journal</target><arg name="author">Kärkkäinen J., Forsström T., Tornaeus J., Wähälä K., Kiuru P., Honkanen A., Stenman U.-H., Turpeinen U., Hesso A.<space/></arg><arg name="date">April 2005<space/></arg><arg name="title">Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues<space/></arg><arg name="journal">Scandinavian Journal of Clinical and Laboratory Investigation<space/></arg><arg name="volume">65<space/></arg><arg name="issue">3<space/></arg><arg name="pages">189–199<space/></arg><arg name="quote"><space/></arg><arg name="doi">10.1080/00365510510013604<space/></arg><arg name="pmid">16095048</arg></template></extension><space/>From then on, two major complementary lines of evidence have been investigated: localization and further characterization of the<space/><italics>N</italics>-methyltransferase enzyme, and<space/><link><target>Analytical chemistry</target><part>analytical studies</part></link>&amp;nbsp;looking for endogenously produced DMT in body fluids and tissues.<extension extension_name='ref' name="pmid779022"></extension></paragraph><paragraph>In 2013 researchers first reported DMT in the<space/><link><target>pineal gland</target></link><space/><link><target>microdialysis</target><part>microdialysate</part></link><space/>of rodents.<extension extension_name='ref' name="pmid23881860"><template><target>cite journal</target><arg name="author">Barker SA, Borjigin J, Lomnicka I, Strassman R<space/></arg><arg name="title">LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate<space/></arg><arg name="journal">Biomed Chromatogr.<space/></arg><arg name="date">Jul 2013<space/></arg><arg name="volume"><space/>27</arg><arg name="issue"><space/>12</arg><arg name="pages"><space/>1690–1700</arg><arg name="pmid">23881860<space/></arg><arg name="doi">10.1002/bmc.2981</arg></template></extension></paragraph><paragraph>A study published in 2014 reported the biosynthesis of N,N-dimethyltryptamine (DMT) in the human melanoma cell line SK-Mel-147 including details on its metabolism by peroxidases.<extension extension_name='ref' name="pmid24508833"><template><target>cite journal</target><arg name="author">Gomes MM, Coimbra JB, Clara RO, Dörr FA, Moreno AC, Chagas JR, Tufik S, Pinto E Jr, Catalani LH, Campa A.<space/></arg><arg name="title">Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases<space/></arg><arg name="journal">Biochemica Pharmacology.<space/></arg><arg name="date">2014<space/></arg><arg name="volume">88<space/></arg><arg name="issue">3<space/></arg><arg name="pages">393–401<space/></arg><arg name="pmid">24508833<space/></arg><arg name="doi">10.1016/j.bcp.2014.01.035</arg></template></extension></paragraph><paragraph>In a 2014 paper a group first demonstrated the immunomodulatory potential of DMT and<space/><link><target>5-MeO-DMT</target></link><space/>through the<space/><link><target>Sigma-1 receptor</target></link><space/>of human immune cells. This immunomodulatory activity may contribute to significant anti-inflammatory effects and tissue regeneration.<extension extension_name='ref' name="pmid25171370"><template><target>cite journal</target><arg name="author">Szabo A, Kovacs A, Frecska E, Rajnavolgyi E.<space/></arg><arg name="title">Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells<space/></arg><arg name="journal">PLoS ONE<space/></arg><arg name="date">29 Aug 2014<space/></arg><arg name="volume">9<space/></arg><arg name="issue">8<space/></arg><arg name="pages">e106533<space/></arg><arg name="pmid">25171370<space/></arg><arg name="doi">10.1371/journal.pone.0106533</arg></template></extension></paragraph><heading level='4'>INMT</heading><paragraph>Before techniques of<space/><link><target>molecular biology</target></link><space/>were used to localize<space/><link><target>indolethylamine N-methyltransferase</target></link><space/>(INMT),<extension extension_name='ref' name="pmid9852119"></extension><extension extension_name='ref' name="pmid10552930"></extension><space/>characterization and localization went on a par: samples of the biological material where INMT is hypothesized to be active are subject to<space/><link><target>enzyme assay</target></link>. Those enzyme assays are performed either with a radiolabeled methyl donor like (<xhtml:sup>14</xhtml:sup>C-CH<xhtml:sub>3</xhtml:sub>)SAM to which known amounts of unlabeled substrates like tryptamine are added<extension extension_name='ref' name="pmid779022"></extension><space/>or with addition of a radiolabeled substrate like (<xhtml:sup>14</xhtml:sup>C)NMT to demonstrate<space/><link><target>in vivo</target></link><space/>formation.<extension extension_name='ref' name="pmid6792104"></extension><extension extension_name='ref' name="pmid14361"></extension><space/>As qualitative determination of the radioactively tagged product of the enzymatic reaction is sufficient to characterize INMT existence and activity (or lack of), analytical methods used in INMT assays are not required to be as sensitive as those needed to directly detect and quantify the minute amounts of endogenously formed DMT (see DMT subsection below). The essentially qualitative method<space/><link><target>thin layer chromatography</target></link><space/>(TLC) was thus used in a vast majority of studies.<extension extension_name='ref' name="pmid779022"></extension><space/>Also, robust evidence that INMT can catalyze transmethylation of tryptamine into NMT and DMT could be provided with<space/><link><target>Isotopic dilution</target><part>reverse isotope dilution analysis</part></link><space/>coupled to<space/><link><target>mass spectrometry</target></link><space/>for rabbit<extension extension_name='ref' name="pmid5150167"><template><target>cite journal</target><arg name="author">Mandel L.R., Rosenzweig S., Kuehl F.A.<space/></arg><arg name="title">Purification and substrate specificity of indoleamine-''N''-methyl transferase<space/></arg><arg name="journal">Biochemical Pharmacology<space/></arg><arg name="volume">20<space/></arg><arg name="issue">3<space/></arg><arg name="pages">712–6<space/></arg><arg name="date">March 1971<space/></arg><arg name="pmid">5150167<space/></arg><arg name="doi">10.1016/0006-2952(71)90158-4<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid1056183"><template><target>cite journal</target><arg name="author">Lin R.-L., Narasimhachari N.<space/></arg><arg name="title">''N''-methylation of 1-methyltryptamines by indolethylamine ''N''-methyltransferase<space/></arg><arg name="journal">Biochemical Pharmacology<space/></arg><arg name="volume">24<space/></arg><arg name="issue">11–12<space/></arg><arg name="pages">1239–40<space/></arg><arg name="date">June 1975<space/></arg><arg name="pmid">1056183<space/></arg><arg name="doi">10.1016/0006-2952(75)90071-4<space/></arg><arg name="url"></arg></template></extension><space/>and human<extension extension_name='ref' name="pmid5034200"><template><target>cite journal</target><arg name="author">Mandel L.R., Ahn H.S., VandenHeuvel W.J.<space/></arg><arg name="title">Indoleamine-''N''-methyl transferase in human lung<space/></arg><arg name="journal">Biochemical Pharmacology<space/></arg><arg name="volume">21<space/></arg><arg name="issue">8<space/></arg><arg name="pages">1197–200<space/></arg><arg name="date">April 1972<space/></arg><arg name="pmid">5034200<space/></arg><arg name="doi">10.1016/0006-2952(72)90113-X<space/></arg><arg name="url"></arg></template></extension><space/>lung during the early 1970s.</paragraph><paragraph>Selectivity rather than sensitivity proved to be an Achilles heel for some TLC methods with the discovery in 19741975 that incubating rat blood cells or brain tissue with (<xhtml:sup>14</xhtml:sup>C-CH<xhtml:sub>3</xhtml:sub>)SAM and NMT as substrate mostly yields tetrahydro--carboline derivatives,<extension extension_name='ref' name="pmid779022"></extension><extension extension_name='ref' name="pmid6792104"></extension><extension extension_name='ref' name="pmid1067427"><template><target>cite journal</target><arg name="author">Rosengarten H., Meller E., Friedhoff A.J.<space/></arg><arg name="title">Possible source of error in studies of enzymatic formation of dimethyltryptamine<space/></arg><arg name="journal">Journal of Psychiatric Research<space/></arg><arg name="volume">13<space/></arg><arg name="issue">1<space/></arg><arg name="pages">23–30<space/></arg><arg name="year">1976<space/></arg><arg name="pmid">1067427<space/></arg><arg name="doi">10.1016/0022-3956(76)90006-6<space/></arg><arg name="url"></arg></template></extension><space/>and negligible amounts of DMT in brain tissue.<extension extension_name='ref' name="pmid779022"></extension><space/>It is indeed simultaneously realized that the TLC methods used thus far in almost all published studies on INMT and DMT biosynthesis are incapable to resolve DMT from those tetrahydro--carbolines.<extension extension_name='ref' name="pmid779022"></extension><space/>These findings are a blow for all previous claims of evidence of INMT activity and DMT biosynthesis in avian<extension extension_name='ref' name="pmid5793241"><template><target>cite journal</target><arg name="author">Morgan M., Mandell A.J.<space/></arg><arg name="title">Indole(ethyl)amine N-methyltransferase in the brain<space/></arg><arg name="journal">Science<space/></arg><arg name="volume">165<space/></arg><arg name="issue">3892<space/></arg><arg name="pages">492–3<space/></arg><arg name="date">August 1969<space/></arg><arg name="pmid">5793241<space/></arg><arg name="doi">10.1126/science.165.3892.492<space/></arg><arg name="url"></arg></template></extension><space/>and mammalian brain,<extension extension_name='ref' name="pmid5279043"><template><target>cite journal</target><arg name="author">Mandell A.J., Morgan M.<space/></arg><arg name="title">Indole(ethyl)amine N-methyltransferase in human brain<space/></arg><arg name="journal">Nature: New Biology<space/></arg><arg name="volume">230<space/></arg><arg name="issue">11<space/></arg><arg name="pages">85–7<space/></arg><arg name="date">March 1971<space/></arg><arg name="pmid">5279043<space/></arg><arg name="doi">10.1038/newbio230085a0<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid4703789"><template><target>cite journal</target><arg name="author">Saavedra J.M., Coyle J.T., Axelrod J.<space/></arg><arg name="title">The distribution and properties of the nonspecific ''N''-methyltransferase in brain<space/></arg><arg name="journal">Journal of Neurochemistry<space/></arg><arg name="volume">20<space/></arg><arg name="issue">3<space/></arg><arg name="pages">743–52<space/></arg><arg name="date">March 1973<space/></arg><arg name="pmid">4703789<space/></arg><arg name="doi">10.1111/j.1471-4159.1973.tb00035.x<space/></arg><arg name="url"></arg></template></extension><space/>including<space/><link><target>in vivo</target></link>,<extension extension_name='ref' name="pmid5059565"><template><target>cite journal</target><arg name="author">Saavedra J.M., Axelrod J.<space/></arg><arg name="title">Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro<space/></arg><arg name="journal">Science<space/></arg><arg name="volume">175<space/></arg><arg name="issue">4028<space/></arg><arg name="pages">1365–6<space/></arg><arg name="date">March 1972<space/></arg><arg name="pmid">5059565<space/></arg><arg name="doi">10.1126/science.175.4028.1365<space/></arg><arg name="url">http://crfdl.org:1111/xmlui/bitstream/handle/123456789/392/1733285.pdf?sequence</arg><arg name="format"><space/>PDF</arg></template></extension><extension extension_name='ref' name="pmid4725358"><template><target>cite journal</target><arg name="author">Wu P.H., Boulton A.A.<space/></arg><arg name="title">Distribution and metabolism of tryptamine in rat brain<space/></arg><arg name="journal">Canadian Journal of Biochemistry<space/></arg><arg name="volume">51<space/></arg><arg name="issue">7<space/></arg><arg name="pages">1104–12<space/></arg><arg name="date">July 1973<space/></arg><arg name="pmid">4725358<space/></arg><arg name="doi">10.1139/o73-144<space/></arg><arg name="url"></arg></template></extension><space/>as they all relied upon use of the problematic TLC methods:<extension extension_name='ref' name="pmid779022"></extension><space/>their validity is doubted in replication studies that make use of improved TLC methods, and fail to evidence DMT-producing INMT activity in rat and human brain tissues.<extension extension_name='ref' name="pmid963555"><template><target>cite journal</target><arg name="author"><space/>Boarder M.R., Rodnight R.<space/></arg><arg name="title">Tryptamine-N-methyltransferase activity in brain tissue: a re-examination<space/></arg><arg name="journal">Brain Research<space/></arg><arg name="volume">114<space/></arg><arg name="issue">2<space/></arg><arg name="pages">359–64<space/></arg><arg name="date">September 1976<space/></arg><arg name="pmid">963555<space/></arg><arg name="doi">10.1016/0006-8993(76)90680-6</arg></template></extension><extension extension_name='ref' name="pmid823298"><template><target>cite journal</target><arg name="author">Gomes U.R., Neethling A.C., Shanley B.C.<space/></arg><arg name="title">Enzymatic ''N''-methylation of indoleamines by mammalian brain: fact or artefact?<space/></arg><arg name="journal">Journal of Neurochemistry<space/></arg><arg name="volume">27<space/></arg><arg name="issue">3<space/></arg><arg name="pages">701–5<space/></arg><arg name="date">September 1976<space/></arg><arg name="pmid">823298<space/></arg><arg name="doi">10.1111/j.1471-4159.1976.tb10397.x<space/></arg><arg name="url"></arg></template></extension><space/>Published in 1978, the last study attempting to evidence<space/><link><target>in vivo</target></link><space/>INMT activity and DMT production in brain (rat) with TLC methods finds biotransformation of radiolabeled tryptamine into DMT to be real but &quot;insignificant&quot;.<extension extension_name='ref' name="pmid279646"><template><target>cite journal</target><arg name="author">Stramentinoli G., Baldessarini R.J.<space/></arg><arg name="title">Lack of enhancement of dimethyltryptamine formation in rat brain and rabbit lung [[in vivo]] by methionine or ''S''-adenosylmethionine<space/></arg><arg name="journal">Journal of Neurochemistry<space/></arg><arg name="volume">31<space/></arg><arg name="issue">4<space/></arg><arg name="pages">1015–20<space/></arg><arg name="date">October 1978<space/></arg><arg name="pmid">279646<space/></arg><arg name="doi">10.1111/j.1471-4159.1978.tb00141.x<space/></arg><arg name="url"></arg></template></extension><space/>Capability of the method used in this latter study to resolve DMT from tetrahydro--carbolines is questioned later.<extension extension_name='ref' name="pmid6792104"></extension><xhtml:br></xhtml:br>To localize INMT, a qualitative leap is accomplished with use of modern techniques of<space/><link><target>molecular biology</target></link>, and of<space/><link><target>immunohistochemistry</target></link>. In humans, a gene encoding INMT is determined to be located on<space/><link><target>Chromosome 7 (human)</target><part>chromosome 7</part></link>.<extension extension_name='ref' name="pmid10552930"></extension><space/><link><target>Northern blot</target><part>Northern blot analyses</part></link><space/>reveal INMT<space/><link><target>messenger RNA</target></link><space/>(mRNA) to be highly expressed in rabbit lung,<extension extension_name='ref' name="pmid9852119"></extension><space/>and in human<space/><link><target>thyroid</target></link>,<space/><link><target>adrenal gland</target></link>, and lung.<extension extension_name='ref' name="pmid10552930"></extension><extension extension_name='ref' name="UniProtO95050"><link type='external' href='http://www.uniprot.org/uniprot/O95050'>General annotation of Human INMT (O95050) entry in UniProtKB/Swiss-Prot</link></extension><space/>Intermediate levels of expression are found in human heart, skeletal muscle, trachea, stomach, small intestine, pancreas, testis, prostate, placenta,<space/><link><target>lymph node</target></link>, and spinal cord.<extension extension_name='ref' name="pmid10552930"></extension><extension extension_name='ref' name="UniProtO95050"></extension><space/>Low to very low levels of expression are noted in rabbit brain,<extension extension_name='ref' name="pmid10552930"></extension><space/>and human<space/><link><target>thymus</target></link>, liver,<space/><link><target>spleen</target></link>, kidney, colon, ovary, and<space/><link><target>bone marrow</target></link>.<extension extension_name='ref' name="pmid10552930"></extension><extension extension_name='ref' name="UniProtO95050"></extension><space/>INMT mRNA expression is absent in human peripheral blood<space/><link><target>White blood cell</target><part>leukocytes</part></link>, whole brain, and in tissue from 7 specific brain regions (thalamus, subthalamic nucleus, caudate nucleus, hippocampus, amygdala, substantia nigra, and corpus callosum).<extension extension_name='ref' name="pmid10552930"></extension><extension extension_name='ref' name="UniProtO95050"></extension><space/><link><target>Immunohistochemistry</target></link><space/>showed INMT to be present in large amounts in<space/><link><target>Goblet cell</target><part>glandular epithelial cells</part></link><space/>of small and large intestines. In 2011, immunohistochemistry revealed the presence of INMT in primate nervous tissue including retina, spinal cord motor neurons, and pineal gland.<extension extension_name='ref' name="Cozzi N.V., Mavlyutov T.A., Thompson M.A., Ruoho A.E. 2011 840.19"><template><target>cite journal</target><arg name="author">Cozzi N.V., Mavlyutov T.A., Thompson M.A., Ruoho A.E.<space/></arg><arg name="title">Indolethylamine N-methyltransferase expression in primate nervous tissue<space/></arg><arg name="journal">Society for Neuroscience Abstracts<space/></arg><arg name="volume">37<space/></arg><arg name="pages"><space/>840.19<space/></arg><arg name="date">2011<space/></arg><arg name="url">http://www.neurophys.wisc.edu/~cozzi/Indolethylamine%20N-methyltransferase%20expression%20in%20primate%20nervous%20tissue.pdf<space/></arg><arg name="format">PDF</arg></template></extension></paragraph><heading level='4'>Endogenous DMT</heading><paragraph>The first claimed detection of mammalian<space/><link><target>endogenous</target></link><space/>DMT was published in June 1965: German researchers F. Franzen and H. Gross report to have evidenced and quantified DMT, along with its<space/><link><target>structural analog</target></link><space/>bufotenin (5-HO-DMT), in human blood and urine.<extension extension_name='ref' name="pmid5839067"><template><target>cite journal</target><arg name="author">Franzen F., Gross H.<space/></arg><arg name="title">Tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine<space/></arg><arg name="journal">Nature<space/></arg><arg name="volume">206<space/></arg><arg name="issue">988<space/></arg><arg name="page">1052<space/></arg><arg name="date">June 1965<space/></arg><arg name="pmid">5839067<space/></arg><arg name="doi">10.1038/2061052a0<space/></arg><arg name="url"></arg><arg name="quote">After the elaboration of sufficiently selective and quantitative procedures, which are discussed elsewhere, we were able to study the occurrence of tryptamine, ''N'',''N''-dimethyltryptamine, ''N'',''N''-dimethyl-5-hydroxytryptamine and 5-hydroxytryptamine in normal human blood and urine. (...) In 11 of 37 probands ''N'',''N''-dimethyltryptamine was demonstrated in blood (...). In the urine 42·95 ± 8·6 μg of dimethyltryptamine/24 h were excreted.</arg></template></extension><space/>In an article published four months later, the method used in their study was strongly criticized, and the credibility of their results challenged.<extension extension_name='ref' name="pmid5860629"><template><target>cite journal</target><arg name="author">Siegel M.<space/></arg><arg name="title">A sensitive method for the detection of N,N-dimethylserotonin (bufotenin) in urine; failure to demonstrate its presence in the urine of schizophrenic and normal subjects<space/></arg><arg name="journal">Journal of Psychiatric Research<space/></arg><arg name="volume">3<space/></arg><arg name="issue">3<space/></arg><arg name="pages">205–11<space/></arg><arg name="date">October 1965<space/></arg><arg name="pmid">5860629<space/></arg><arg name="doi">10.1016/0022-3956(65)90030-0<space/></arg><arg name="url"></arg></template></extension></paragraph><paragraph>Few of the analytical methods used prior to 2001 to measure levels of endogenously formed DMT had enough sensitivity and selectivity to produce reliable results.<extension extension_name='ref' name="pmid11232854"><template><target>cite journal</target><arg name="author">Barker S.A., Littlefield-Chabaud M.A., David C.<space/></arg><arg name="title">Distribution of the hallucinogens ''N'',''N''-dimethyltryptamine and 5-methoxy-''N'',''N''-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method<space/></arg><arg name="journal">Journal of Chromatography B<space/></arg><arg name="volume">751<space/></arg><arg name="issue">1<space/></arg><arg name="pages">37–47<space/></arg><arg name="date">February 2001<space/></arg><arg name="pmid">11232854<space/></arg><arg name="doi">10.1016/S0378-4347(00)00442-4<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid11763413"><template><target>cite journal</target><arg name="author">Forsström T., Tuominen J., Karkkäinen J.<space/></arg><arg name="title">Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS<space/></arg><arg name="journal">Scandinavian Journal of Clinical and Laboratory Investigation<space/></arg><arg name="volume">61<space/></arg><arg name="issue">7<space/></arg><arg name="pages">547–56<space/></arg><arg name="year">2001<space/></arg><arg name="pmid">11763413<space/></arg><arg name="doi">10.1080/003655101753218319<space/></arg><arg name="url"></arg></template></extension><space/><link><target>Gas chromatography</target></link>, preferably coupled to<space/><link><target>mass spectrometry</target></link><space/>(<link><target>GC-MS</target></link>), is considered a minimum requirement.<extension extension_name='ref' name="pmid11763413"></extension><space/>A study published in 2005<extension extension_name='ref' name="pmid16095048"></extension><space/>implements the most sensitive and selective method ever used to measure endogenous DMT:<extension extension_name='ref' name="pmid20523750"><template><target>cite journal</target><arg name="author">Shen H.W., Jiang X.L., Yu A.M.<space/></arg><arg name="title">Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study<space/></arg><arg name="journal">Bioanalysis<space/></arg><arg name="volume">1<space/></arg><arg name="issue">1<space/></arg><arg name="pages">87–95<space/></arg><arg name="date">April 2009<space/></arg><arg name="pmid">20523750<space/></arg><arg name="pmc">2879651<space/></arg><arg name="doi">10.4155/bio.09.7<space/></arg></template></extension><space/><link><target>High-performance liquid chromatography</target><part>liquid chromatography</part></link>-<link><target>tandem mass spectrometry</target></link><space/>with<space/><link><target>electrospray ionization</target></link><space/>(LC-ESI-MS/MS) allows for reaching limits of detection (LODs) 12 to 200 fold lower than those attained by the best methods employed in the 1970s. The data summarized in the table below are from studies conforming to the abovementioned requirements (abbreviations used: CSF =<space/><link><target>cerebrospinal fluid</target></link>; LOD =<space/><link><target>limit of detection</target></link>; n = number of samples; ng/L and ng/kg = nanograms (10<xhtml:sup>9</xhtml:sup><space/>g) per litre, and nanograms per kilogram, respectively):</paragraph><table border="1" cellpadding="2" cellspacing="1" style="margin: 1em auto 1em auto; width:70%;" class="wikitable"><tablecaption align="bottom"><bold>DMT</bold><space/>in body fluids and tissues<space/><italics>(NB: units have been harmonized)</italics></tablecaption><tablerow><tablehead style="background:azure; vertical-align:middle; text-align:center; width:30px;">Species</tablehead><tablehead style="background:azure; vertical-align:middle; text-align:center; width:60px;">Sample</tablehead><tablehead style="background:azure; vertical-align:middle; text-align:center; width:400px;">Results</tablehead></tablerow><tablerow><tablehead rowspan="8" style="background:oldLace; vertical-align:top; text-align:center; width:30px;">Human</tablehead><tablecell style="vertical-align:middle; background:oldLace; width:60px;"><link><target>Blood serum</target></link></tablecell><tablecell style="vertical-align:middle; background:oldLace; width:400px;">&amp;lt; LOD (n = 66)<extension extension_name='ref' name="pmid16095048"></extension></tablecell></tablerow><tablerow><tablecell style="vertical-align:middle; background:oldLace; width:60px;"><link><target>Blood plasma</target></link></tablecell><tablecell style="vertical-align:middle; background:oldLace; width:400px;">&amp;lt; LOD (n = 71)<extension extension_name='ref' name="pmid16095048"></extension><space/>&amp;nbsp;&amp;nbsp; &amp;lt; LOD (n = 38); 1,000 &amp; 10,600&amp;nbsp;ng/L (n = 2)<extension extension_name='ref' name="pmid4517484"><template><target>cite journal</target><arg name="author">Wyatt R.J., Mandel L.R., Ahn H.S., Walker R.W., Vanden Heuvel W.J.<space/></arg><arg name="title">Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients<space/></arg><arg name="journal">Psychopharmacologia<space/></arg><arg name="volume">31<space/></arg><arg name="issue">3<space/></arg><arg name="pages">265–70<space/></arg><arg name="date">July 1973<space/></arg><arg name="pmid">4517484<space/></arg><arg name="doi">10.1007/BF00422516<space/></arg><arg name="url">http://www.springerlink.com/content/j686565850024164/fulltext.pdf<space/></arg><arg name="format">PDF</arg></template></extension></tablecell></tablerow><tablerow><tablecell style="vertical-align:middle; background:oldLace; width:60px;">Whole blood</tablecell><tablecell style="vertical-align:middle; background:oldLace; width:400px;">&amp;lt; LOD (n = 20); 50790&amp;nbsp;ng/L (n = 20)<extension extension_name='ref' name="pmid803203"><template><target>cite journal</target><arg name="author">Angrist B., Gershon S., Sathananthan G., Walker R.W., Lopez-Ramos B., Mandel L.R., Vandenheuvel W.J.<space/></arg><arg name="title">Dimethyltryptamine levels in blood of schizophrenic patients and control subjects<space/></arg><arg name="journal">Psychopharmacology<space/></arg><arg name="volume">47<space/></arg><arg name="issue">1<space/></arg><arg name="pages">29–32<space/></arg><arg name="date">May 1976<space/></arg><arg name="pmid">803203<space/></arg><arg name="doi">10.1007/BF00428697<space/></arg><arg name="url">http://www.springerlink.com/content/kw2nm252m3248864/fulltext.pdf<space/></arg><arg name="format">PDF</arg></template></extension></tablecell></tablerow><tablerow><tablecell style="vertical-align:middle; background:oldLace; width:60px;">Urine</tablecell><tablecell style="vertical-align:middle; background:oldLace; width:400px;">&amp;lt; 100&amp;nbsp;ng/L (n = 9)<extension extension_name='ref' name="pmid16095048"></extension><space/>&amp;nbsp;&amp;nbsp; &amp;lt; LOD (n = 60); 160540&amp;nbsp;ng/L (n = 5)<extension extension_name='ref' name="pmid11763413"></extension><space/>&amp;nbsp;&amp;nbsp; Detected in n = 10 by GC-MS<extension extension_name='ref' name="pmid271509"><template><target>cite journal</target><arg name="author">Oon M.C., Rodnight R.<space/></arg><arg name="title">A gas chromatographic procedure for determining ''N'', ''N''-dimethyltryptamine and ''N''-monomethyltryptamine in urine using a nitrogen detector<space/></arg><arg name="journal">Biochemical Medicine<space/></arg><arg name="volume">18<space/></arg><arg name="issue">3<space/></arg><arg name="pages">410–9<space/></arg><arg name="date">December 1977<space/></arg><arg name="pmid">271509<space/></arg><arg name="doi">10.1016/0006-2944(77)90077-1<space/></arg><arg name="url"></arg></template></extension></tablecell></tablerow><tablerow style="vertical-align:middle; background:oldLace;"><tablecell style="width:60px;">Feces</tablecell><tablecell style="width:400px;">&amp;lt; 50&amp;nbsp;ng/kg (n&amp;nbsp;= 12); 130&amp;nbsp;ng/kg (n = 1)<extension extension_name='ref' name="pmid16095048"></extension></tablecell></tablerow><tablerow style="vertical-align:middle; background:oldLace;"><tablecell style="width:60px;">Kidney</tablecell><tablecell style="width:400px;">15&amp;nbsp;ng/kg (n = 1)<extension extension_name='ref' name="pmid16095048"></extension></tablecell></tablerow><tablerow style="vertical-align:middle; background:oldLace;"><tablecell style="width:60px;">Lung</tablecell><tablecell style="width:400px;">14&amp;nbsp;ng/kg (n = 1)<extension extension_name='ref' name="pmid16095048"></extension></tablecell></tablerow><tablerow><tablecell style="vertical-align:middle; background:oldLace; width:60px;"><link><target>Lumbar puncture</target><part>Lumbar</part></link><space/>CSF</tablecell><tablecell style="vertical-align:middle; background:oldLace; width:400px;">100,370&amp;nbsp;ng/L (n = 1); 2,3307,210&amp;nbsp;ng/L (n = 3); 350 &amp; 850&amp;nbsp;ng/L (n = 2)<extension extension_name='ref' name="pmid289421"><template><target>cite journal</target><arg name="author">Smythies J.R., Morin R.D., Brown G.B.<space/></arg><arg name="title">Identification of dimethyltryptamine and ''O''-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry<space/></arg><arg name="journal">Biological Psychiatry<space/></arg><arg name="volume">14<space/></arg><arg name="issue">3<space/></arg><arg name="pages">549–56<space/></arg><arg name="date">June 1979<space/></arg><arg name="pmid">289421<space/></arg><arg name="doi"><space/></arg><arg name="url"></arg></template></extension></tablecell></tablerow><tablerow><tablehead rowspan="4" style="background:#dcdcdc; vertical-align:top; text-align:center; width:30px;">Rat</tablehead><tablecell style="vertical-align:middle; background:#dcdcdc; width:60px;">Kidney</tablecell><tablecell style="vertical-align:middle; background:#dcdcdc; width:400px;">12 &amp;amp;16&amp;nbsp;ng/kg (n = 2)<extension extension_name='ref' name="pmid16095048"></extension></tablecell></tablerow><tablerow style="vertical-align:middle; background:#dcdcdc;"><tablecell style="width:60px;">Lung</tablecell><tablecell style="width:400px;">22 &amp; 12&amp;nbsp;ng/kg (n = 2)<extension extension_name='ref' name="pmid16095048"></extension></tablecell></tablerow><tablerow style="vertical-align:middle; background:#dcdcdc;"><tablecell style="width:60px;">Liver</tablecell><tablecell style="width:400px;">6 &amp; 10&amp;nbsp;ng/kg (n = 2)<extension extension_name='ref' name="pmid16095048"></extension></tablecell></tablerow><tablerow><tablecell style="vertical-align:middle; background:#dcdcdc; width:60px;">Brain</tablecell><tablecell style="vertical-align:middle; background:#dcdcdc; width:400px;">10 &amp;amp;15&amp;nbsp;ng/kg (n = 2)<extension extension_name='ref' name="pmid16095048"></extension><space/>&amp;nbsp; &amp;nbsp;Measured in<space/><link><target>Synaptic vesicle</target><part>synaptic vesicular</part></link><space/><link><target>Fractionation</target><part>fraction</part></link><extension extension_name='ref' name="pmid20877"><template><target>cite journal</target><arg name="author">Christian S.T., Harrison R., Quayle E., Pagel J., Monti J.<space/></arg><arg name="title">The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent<space/></arg><arg name="journal">Biochemical Medicine<space/></arg><arg name="volume">18<space/></arg><arg name="issue">2<space/></arg><arg name="pages">164–83<space/></arg><arg name="date">October 1977<space/></arg><arg name="pmid">20877<space/></arg><arg name="doi">10.1016/0006-2944(77)90088-6<space/></arg><arg name="url"></arg></template></extension></tablecell></tablerow><tablerow><tablehead style="vertical-align:middle; background:honeyDew; width:30px;">Rabbit</tablehead><tablecell style="vertical-align:middle; background:honeyDew; width:60px;">Liver</tablecell><tablecell style="vertical-align:middle; background:honeyDew; width:400px;">&amp;lt; 10&amp;nbsp;ng/kg (n = 1)<extension extension_name='ref' name="pmid16095048"></extension></tablecell></tablerow></table><paragraph>A 2013 study found DMT in<space/><link><target>Microdialysis</target><part>microdialysate</part></link><space/>obtained from a rat's pineal gland, providing evidence of endogenous DMT in the mammalian brain.<extension extension_name='ref' name="pmid23881860"></extension></paragraph><heading level='2'>Physical and chemical properties</heading><paragraph><link><target>File:D-Tryp.jpg</target><part>thumb</part><part>DMT crystals</part></link><link><target>Image:Dmtx400tt9.jpg</target><part>thumb</part><part>right</part><part>DMT crystal at 400 magnification</part></link>DMT is commonly handled and stored as a<space/><link><target>fumaric acid</target><part>fumarate</part></link>,<extension extension_name='ref' name="erowid.org">https://www.erowid.org/library/books_online/tihkal/tihkal06.shtml</extension><space/>as other DMT acid salts are extremely<space/><link><target>Hygroscopy</target><part>hygroscopic</part></link><space/>and will not readily crystallize. Its<space/><link><target>Freebase (chemistry)</target><part>freebase</part></link><space/>form, although less stable than DMT fumarate, is favored by recreational users choosing to vaporize the chemical as it has a lower boiling point.<extension extension_name='ref' name="erowid.org"></extension><space/>In contrast to DMT's base, its salts are water-soluble. DMT in solution degrades relatively quickly and should be stored protected from air, light, and heat in a freezer.<template><target>citation needed</target><arg name="date">October 2012</arg></template></paragraph><heading level='3'>As distinguished from 5-MeO-DMT</heading><paragraph><link><target>5-MeO-DMT</target></link>, a psychedelic drug structurally similar to<space/><italics>N</italics>,<italics>N</italics>-DMT, is sometimes referred to as DMT through abbreviation. As a white, crystalline solid, it is also similar in appearance to DMT. However, it is considerably more potent (5-MeO-DMT typical vaporized dose: 520&amp;nbsp;mg), and care should be taken to clearly differentiate between the two drugs to avoid accidental overdose.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.erowid.org/chemicals/5meo_dmt/5meo_dmt_dose.shtml<space/></arg><arg name="title">5-MeO-DMT dosage<space/></arg><arg name="author">Erowid<space/></arg><arg name="date">14 February 1999<space/></arg><arg name="work">Erowid 5-MeO-DMT Vault<space/></arg><arg name="accessdate">8 December 2010</arg></template></extension></paragraph><heading level='2'>Pharmacology</heading><heading level='3'>Pharmacokinetics</heading><paragraph>DMT peak level concentrations (<italics>C</italics><xhtml:sub>max</xhtml:sub>) measured in whole blood after intramuscular (IM) injection (0.7&amp;nbsp;mg/kg, n = 11)<extension extension_name='ref' name="pmid4607811"><template><target>cite journal</target><arg name="author">Kaplan J., Mandel L.R., Stillman R., Walker R.W., VandenHeuvel W.J., Gillin J.C., Wyatt R.J.<space/></arg><arg name="title">Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects<space/></arg><arg name="journal">Psychopharmacologia<space/></arg><arg name="volume">38<space/></arg><arg name="issue">3<space/></arg><arg name="pages">239–45<space/></arg><arg name="year">1974<space/></arg><arg name="pmid">4607811<space/></arg><arg name="doi">10.1007/BF00421376<space/></arg><arg name="url">http://www.springerlink.com/content/v22655wm10341746/fulltext.pdf<space/></arg><arg name="format">PDF</arg></template></extension><space/>and in plasma following intravenous (IV) administration (0.4&amp;nbsp;mg/kg, n = 10)<extension extension_name='ref' name="pmid8297216"><template><target>cite journal</target><arg name="author">Strassman R.J., Qualls C.R.<space/></arg><arg name="title">Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects<space/></arg><arg name="journal">Archives of General Psychiatry<space/></arg><arg name="volume">51<space/></arg><arg name="issue">2<space/></arg><arg name="pages">85–97<space/></arg><arg name="date">February 1994<space/></arg><arg name="pmid">8297216<space/></arg><arg name="doi"><space/>10.1001/archpsyc.1994.03950020009001</arg><arg name="url"></arg></template></extension><space/>of fully psychedelic doses are in the range of 14 to 154 g/L and 32 to 204 g/L, respectively.The corresponding<space/><link><target>molar concentration</target><trail>s</trail></link><space/>of DMT are therefore in the range of 0.0740.818 M in whole blood and 0.1701.08 M in plasma. However, several studies have described active transport and accumulation of DMT into rat and dog brain following peripheral administration.<extension extension_name='ref' name="pmid6812592"><template><target>cite journal</target><arg name="author">Barker S.A., Beaton J.M., Christian S.T., Monti J.A., Morris P.E.<space/></arg><arg name="title">Comparison of the brain levels of N,N-dimethyltryptamine and α, α, β, β-tetradeutero-N-N-dimethyltryptamine following intraperitoneal injection. The in vivo kinetic isotope effect<space/></arg><arg name="journal">[[Biochemical Pharmacology]]<space/></arg><arg name="volume">31<space/></arg><arg name="issue">15<space/></arg><arg name="pages">2513–6<space/></arg><arg name="date">August 1982<space/></arg><arg name="pmid">6812592<space/></arg><arg name="doi">10.1016/0006-2952(82)90062-4<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid41604"><template><target>cite journal</target><arg name="author">Sangiah S., Gomez M.V., Domino E.F.<space/></arg><arg name="title">Accumulation of ''N,N''-dimethyltryptamine in rat brain cortical slices<space/></arg><arg name="journal">Biological Psychiatry<space/></arg><arg name="volume">14<space/></arg><arg name="issue">6<space/></arg><arg name="pages">925–36<space/></arg><arg name="date">December 1979<space/></arg><arg name="pmid">41604</arg></template></extension><extension extension_name='ref' name="pmid3472526"><template><target>cite journal</target><arg name="author">Sitaram B.R., Lockett L., Talomsin R., Blackman G.L., McLeod W.R.<space/></arg><arg name="title">''In vivo'' metabolism of 5-methoxy-''N,N''-dimethyltryptamine and ''N,N''-dimethyltryptamine in the rat<space/></arg><arg name="journal">Biochemical Pharmacology<space/></arg><arg name="volume">36<space/></arg><arg name="issue">9<space/></arg><arg name="pages">1509–12<space/></arg><arg name="date">May 1987<space/></arg><arg name="pmid">3472526<space/></arg><arg name="doi">10.1016/0006-2952(87)90118-3</arg></template></extension><extension extension_name='ref' name="pmid3866749"><template><target>cite journal</target><arg name="author">Takahashi T., Takahashi K., Ido T., Yanai K., Iwata R., Ishiwata K., Nozoe S.<space/></arg><arg name="title"><space/>[<sup>11</sup>C]-labeling of indolealkylamine alkaloids and the comparative study of their tissue distributions<space/></arg><arg name="journal">International Journal of Applied Radiation and Isotopes<space/></arg><arg name="volume">36<space/></arg><arg name="issue">12<space/></arg><arg name="pages">965–9<space/></arg><arg name="date">December 1985<space/></arg><arg name="pmid">3866749<space/></arg><arg name="doi">10.1016/0020-708X(85)90257-1</arg></template></extension><extension extension_name='ref' name="pmid3489620"><template><target>cite journal</target><arg name="author">Yanai K., Ido T., Ishiwata K., Hatazawa J, Takahashi T., Iwata R., Matsuzawa T.<space/></arg><arg name="title">''In vivo'' kinetics and displacement study of a carbon-11-labeled hallucinogen, ''N,N''-(<sup>11</sup>C)dimethyltryptamine<space/></arg><arg name="journal">European Journal of Nuclear Medicine<space/></arg><arg name="volume">12<space/></arg><arg name="issue">3<space/></arg><arg name="pages">141–6<space/></arg><arg name="year">1986<space/></arg><arg name="pmid">3489620<space/></arg><arg name="doi">10.1007/BF00276707<space/></arg><arg name="url">http://www.springerlink.com/content/j2l4821226141002/fulltext.pdf<space/></arg><arg name="format">PDF</arg></template></extension>Similar active transport, and accumulation processes likely occur in human brain and may concentrate DMT in brain by several-fold or more (relatively to blood), resulting in local concentrations in the micromolar or higher range. Such concentrations would be commensurate with serotonin brain tissue concentrations, which have been consistently determined to be in the 1.5-4 M range.<extension extension_name='ref' name="pmid20723248"><template><target>cite journal</target><arg name="author1">Best, J.<space/></arg><arg name="author2">Nijhout, H. F.<space/></arg><arg name="author3">Reed, M.<space/></arg><arg name="title">Serotonin synthesis, release and reuptake in terminals: a mathematical model<space/></arg><arg name="journal">Theoretical Biology & Medical Modelling<space/></arg><arg name="volume">7<space/></arg><arg name="issue">1<space/></arg><arg name="page">34<space/></arg><arg name="year">2010<space/></arg><arg name="pmid">20723248<space/></arg><arg name="pmc">2942809<space/></arg><arg name="doi">10.1186/1742-4682-7-34</arg></template></extension><extension extension_name='ref' name="pmid16146432"><template><target>cite journal</target><arg name="author1">Merrill, M. A.<space/></arg><arg name="author2">Clough, R. W.<space/></arg><arg name="author3">Jobe, P. C.<space/></arg><arg name="author4">Browning R. A.<space/></arg><arg name="title">Brainstem seizure severity regulates forebrain seizure expression in the audiogenic kindling model<space/></arg><arg name="journal">Epilepsia<space/></arg><arg name="volume">46<space/></arg><arg name="issue">9<space/></arg><arg name="pages">1380–8<space/></arg><arg name="date">September 2005<space/></arg><arg name="pmid">16146432<space/></arg><arg name="doi">10.1111/j.1528-1167.2005.39404.x<space/></arg><arg name="url">http://assets0.pubget.com/pdf/16146432.pdf<space/></arg><arg name="format">PDF</arg></template></extension></paragraph><paragraph>Closely coextending with peak psychedelic effects, mean time to reach peak concentrations (<italics>T</italics><xhtml:sub>max</xhtml:sub>) was determined to be 1015 minutes in whole blood after IM injection,<extension extension_name='ref' name="pmid4607811"></extension><space/>and 2 minutes in plasma after IV administration.<extension extension_name='ref' name="pmid8297216"></extension><space/>When taken orally mixed in an<space/><link><target>ayahuasca</target></link><space/>decoction, and in<space/><link><target>Freeze-drying</target><part>freeze-dried</part></link><space/>ayahuasca<space/><link><target>Capsule (pharmacy)#Two-piece gel encapsulation</target><part>gel caps</part></link>, DMT<space/><italics>T</italics><xhtml:sub>max</xhtml:sub><space/>is considerably delayed: 107.59 32.5 minutes,<extension extension_name='ref' name="pmid10404423"><template><target>cite journal</target><arg name="author">Callaway J.C., McKenna D.J., Grob C.S., Brito G.S., Raymon L.P., Poland R.E., Andrade E.N.</arg><arg name="title">Pharmacokinetics of ''Hoasca'' alkaloids in healthy humans<space/></arg><arg name="journal">Journal of Ethnopharmacology<space/></arg><arg name="volume">65<space/></arg><arg name="issue">3<space/></arg><arg name="pages">243–56<space/></arg><arg name="date">June 1999<space/></arg><arg name="pmid">10404423<space/></arg><arg name="doi">10.1016/S0378-8741(98)00168-8<space/></arg><arg name="url">http://wiki.dmt-nexus.com/w/images/2/26/Pharmacokinetics_of_hoasca_in_healthy_humans.pdf<space/></arg><arg name="format">PDF</arg><arg name="display-authors">etal</arg></template></extension><space/>and 90120 minutes,<extension extension_name='ref' name="pmid12660312"><template><target>cite journal</target><arg name="author">Riba J., Valle M., Urbano G., Yritia M., Morte A., Barbanoj M.J.<space/></arg><arg name="title">Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics<space/></arg><arg name="journal">Journal of Pharmacology and Experimental Therapeutics<space/></arg><arg name="volume">306<space/></arg><arg name="issue">1<space/></arg><arg name="pages">73–83<space/></arg><arg name="date">July 2003<space/></arg><arg name="pmid">12660312<space/></arg><arg name="doi">10.1124/jpet.103.049882<space/></arg><arg name="url">http://jpet.aspetjournals.org/content/306/1/73.full.pdf<space/></arg><arg name="format">PDF</arg></template></extension><space/>respectively.The pharmacokinetics for vaporizing DMT have not been studied or reported.</paragraph><heading level='3'>Pharmacodynamics</heading><paragraph>DMT binds non-<link><target>binding selectivity</target><part>selectively</part></link><space/>with<space/><link><target>affinity (pharmacology)</target><part>affinities</part></link><space/>&lt; 0.6 M to the following<space/><link><target>serotonin receptor</target><trail>s</trail></link>:<space/><link><target>5-HT1A receptor</target><part>5-HT<xhtml:sub>1A</xhtml:sub></part></link>,<extension extension_name='ref' name="pmid19881490"><template><target>cite journal</target><arg name="author">Keiser M.J., Setola V., Irwin J.J., Laggner C., Abbas A.I., Hufeisen S.J., Jensen N.H.</arg><arg name="title">Predicting new molecular targets for known drugs<space/></arg><arg name="journal">Nature<space/></arg><arg name="volume">462<space/></arg><arg name="issue">7270<space/></arg><arg name="pages">175–81<space/></arg><arg name="date">November 2009<space/></arg><arg name="pmid">19881490<space/></arg><arg name="pmc">2784146<space/></arg><arg name="doi">10.1038/nature08506<space/></arg><arg name="display-authors">etal</arg></template></extension><extension extension_name='ref' name="pmid1828347"><template><target>cite journal</target><arg name="author">Deliganis A.V., Pierce P.A., Peroutka S.J.<space/></arg><arg name="title">Differential interactions of dimethyltryptamine (DMT) with 5-HT<sub>1A</sub><space/>and 5-HT<sub>2</sub><space/>receptors<space/></arg><arg name="journal">Biochemical Pharmacology<space/></arg><arg name="volume">41<space/></arg><arg name="issue">11<space/></arg><arg name="pages">1739–44<space/></arg><arg name="date">June 1991<space/></arg><arg name="pmid">1828347<space/></arg><arg name="doi">10.1016/0006-2952(91)90178-8<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid2540505"><template><target>cite journal</target><arg name="author">Pierce P.A., Peroutka S.J.<space/></arg><arg name="title">Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex<space/></arg><arg name="journal">Psychopharmacology<space/></arg><arg name="volume">97<space/></arg><arg name="issue">1<space/></arg><arg name="pages">118–22<space/></arg><arg name="year"><space/>1989<space/></arg><arg name="pmid">2540505<space/></arg><arg name="doi">10.1007/BF00443425<space/></arg><arg name="url">http://www.springerlink.com/content/p071q46411657071/fulltext.pdf<space/></arg><arg name="format">PDF</arg></template></extension><space/><link><target>5-HT1B receptor</target><part>5-HT<xhtml:sub>1B</xhtml:sub></part></link>,<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid20126400"><template><target>cite journal</target><arg name="author">Ray T.S.<space/></arg><arg name="title"><space/>Psychedelics and the Human Receptorome<space/></arg><arg name="journal"><space/>PLoS ONE<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>e9019<space/></arg><arg name="year">2010<space/></arg><arg name="pmid"><space/>20126400<space/></arg><arg name="pmc"><space/>2814854<space/></arg><arg name="doi"><space/>10.1371/journal.pone.0009019<space/></arg><arg name="url"><space/>http://dx.plos.org/10.1371/journal.pone.0009019<space/></arg><arg name="editor1-last">Manzoni<space/></arg><arg name="editor1-first">Olivier Jacques</arg></template></extension><space/><link><target>5-HT1D receptor</target><part>5-HT<xhtml:sub>1D</xhtml:sub></part></link>,<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid2540505"></extension><extension extension_name='ref' name="pmid20126400"></extension><space/><link><target>5-HT2A receptor</target><part>5-HT<xhtml:sub>2A</xhtml:sub></part></link>,<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid2540505"></extension><extension extension_name='ref' name="pmid20126400"></extension><extension extension_name='ref' name="pmid9768567"><template><target>cite journal</target><arg name="author"><space/>Smith R.L., Canton H., Barrett R.J., Sanders-Bush E.<space/></arg><arg name="title">Agonist properties of ''N'',''N''-dimethyltryptamine at serotonin 5-HT<sub>2A</sub><space/>and 5-HT<sub>2C</sub><space/>receptors<space/></arg><arg name="journal">Pharmacology, Biochemistry, and Behavior<space/></arg><arg name="volume"><space/>61<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>323–30<space/></arg><arg name="date">November 1998<space/></arg><arg name="pmid"><space/>9768567<space/></arg><arg name="doi"><space/>10.1016/S0091-3057(98)00110-5<space/></arg><arg name="url">http://crfdl.org:1111/xmlui/bitstream/handle/123456789/17/Agonist%20Properties%20of%20N,N-Dimethyltryptaminenext%20term%20at%20Ser.pdf<space/></arg><arg name="format">PDF</arg></template></extension><space/><link><target>5-HT2B receptor</target><part>5-HT<xhtml:sub>2B</xhtml:sub></part></link>,<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid20126400"></extension><space/><link><target>5-HT2C receptor</target><part>5-HT<xhtml:sub>2C</xhtml:sub></part></link>,<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid20126400"></extension><extension extension_name='ref' name="pmid9768567"></extension><space/><link><target>5-HT6 receptor</target><part>5-HT<xhtml:sub>6</xhtml:sub></part></link>,<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid20126400"></extension><space/>and<space/><link><target>5-HT7 receptor</target><part>5-HT<xhtml:sub>7</xhtml:sub></part></link>.<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid20126400"></extension><space/>An<space/><link><target>agonist</target></link><space/>action has been determined at 5-HT<xhtml:sub>1A</xhtml:sub>,<extension extension_name='ref' name="pmid1828347"></extension><space/>5-HT<xhtml:sub>2A</xhtml:sub><space/>and 5-HT<xhtml:sub>2C</xhtml:sub>.<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid20126400"></extension><extension extension_name='ref' name="pmid9768567"></extension><space/>Its<space/><link><target>intrinsic activity</target><part>efficacies</part></link><space/>at other serotonin receptors remain to be determined. Of special interest will be the determination of its efficacy at human 5-HT<xhtml:sub>2B</xhtml:sub><space/>receptor as two<space/><italics>in vitro</italics><space/>assays evidenced DMT's high affinity for this receptor: 0.108 M<extension extension_name='ref' name="pmid20126400"></extension><space/>and 0.184 M.<extension extension_name='ref' name="pmid19881490"></extension><space/>This may be of importance because chronic or frequent uses of serotonergic drugs showing preferential high affinity and clear agonism at 5-HT<xhtml:sub>2B</xhtml:sub><space/>receptor have been causally linked to<space/><link><target>valvular heart disease</target></link>.<extension extension_name='ref' name="pmid19505264"><template><target>cite journal</target><arg name="author">Rothman R.B., Baumann M.H.<space/></arg><arg name="title">Serotonergic Drugs and Valvular Heart Disease<space/></arg><arg name="journal">Expert Opinion on Drug Safety<space/></arg><arg name="volume">8<space/></arg><arg name="issue">3<space/></arg><arg name="pages">317–29<space/></arg><arg name="date">May 2009<space/></arg><arg name="pmid">19505264<space/></arg><arg name="pmc">2695569<space/></arg><arg name="doi">10.1517/14740330902931524<space/></arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref' name="pmid17202450"><template><target>cite journal</target><arg name="author">Roth B.L.<space/></arg><arg name="title">Drugs and valvular heart disease<space/></arg><arg name="journal">New England Journal of Medicine<space/></arg><arg name="volume">356<space/></arg><arg name="issue">1<space/></arg><arg name="pages">6–9<space/></arg><arg name="date">January 2007<space/></arg><arg name="pmid">17202450<space/></arg><arg name="doi">10.1056/NEJMp068265</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Jonathan D. Urban, William P. Clarke, Mark von Zastrow, David E. Nichols, Brian Kobilka, Harel Weinstein, Jonathan A. Javitch, Bryan L. Roth, Arthur Christopoulos, Patrick M. Sexton, Keith J. Miller, Michael Spedding and Richard B. Mailman<space/></arg><arg name="title">Functional Selectivity and Classical Concepts of Quantitative Pharmacology<space/></arg><arg name="journal">JPET<space/></arg><arg name="volume">320<space/></arg><arg name="issue">1<space/></arg><arg name="pages">1–13<space/></arg><arg name="date">2006-06-27<space/></arg><arg name="doi">10.1124/jpet.106.104463<space/></arg><arg name="pmid">16803859</arg></template></extension></paragraph><paragraph>It has also been shown to possess affinity for the<space/><link><target>dopamine</target></link><space/><link><target>D1 receptor</target><part>D<xhtml:sub>1</xhtml:sub></part></link>,<space/><link><target>1-adrenergic receptor</target><part><xhtml:sub>1</xhtml:sub>-adrenergic</part></link>,<space/><link><target>2-adrenergic receptor</target><part><xhtml:sub>2</xhtml:sub>-adrenergic</part></link>,<space/><link><target>Imidazoline receptor</target><part>imidazoline-1</part></link>, and<space/><link><target>sigma-1 receptor</target><part>sigma-1</part></link><space/>(<xhtml:sub>1</xhtml:sub>)<space/><link><target>receptor (biochemistry)</target><part>receptors</part></link>.<extension extension_name='ref' name="pmid2540505"></extension><extension extension_name='ref' name="pmid20126400"></extension><extension extension_name='ref' name="pmid16962229"><template><target>cite journal</target><arg name="last1">Burchett<space/></arg><arg name="first1">Scott A.<space/></arg><arg name="last2">Hicks<space/></arg><arg name="first2">T. Philip<space/></arg><arg name="title">The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain<space/></arg><arg name="journal">Progress in Neurobiology<space/></arg><arg name="date">August 2006<space/></arg><arg name="volume">79<space/></arg><arg name="issue">5–6<space/></arg><arg name="pages">223–46<space/></arg><arg name="url">http://www.mimosahostilis.com/files/The%20mysterious%20trace%20amines%20%20protean%20neuromodulato.pdf<space/></arg><arg name="accessdate">9 May 2012<space/></arg><arg name="format">PDF<space/></arg><arg name="doi">10.1016/j.pneurobio.2006.07.003<space/></arg><arg name="pmid">16962229<space/></arg><arg name="issn">0301-0082<space/></arg><arg name="oclc">231983957</arg></template></extension><space/>Converging lines of evidence established activation of the<space/><xhtml:sub>1</xhtml:sub><space/>receptor at concentrations of 50100 M.<extension extension_name='ref' name="pmid19213917"><template><target>cite journal</target><arg name="author">Fontanilla D., Johannessen M., Hajipour A.R., Cozzi N.V., Jackson M.B., Ruoho A.E.<space/></arg><arg name="title">The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator<space/></arg><arg name="journal">Science<space/></arg><arg name="volume">323<space/></arg><arg name="issue">5916<space/></arg><arg name="pages">934–7<space/></arg><arg name="date">February 2009<space/></arg><arg name="pmid">19213917<space/></arg><arg name="pmc">2947205<space/></arg><arg name="doi">10.1126/science.1166127<space/></arg><arg name="url"><space/>http://www.sciencemag.org/cgi/pmidlookup?view</arg></template></extension><space/>Its efficacies at the other receptor binding sites are unclear. It has also been shown<space/><italics>in vitro</italics><space/>to be a<space/><link><target>substrate (biochemistry)</target><part>substrate</part></link><space/>for the cell-surface<space/><link><target>serotonin transporter</target></link><space/>(SERT) and the intracellular<space/><link><target>vesicular monoamine transporter 2</target></link><space/>(VMAT2), inhibiting SERT-mediated serotonin uptake in human platelets at an average concentration of 4.00 0.70 M and VMAT2-mediated serotonin uptake in vesicles (of<space/><link><target>Fall armyworm</target><part>army worm</part></link><space/>Sf9 cells) expressing rat VMAT2 at an average concentration of 93 6.8 M.<extension extension_name='ref' name="pmid19756361"><template><target>cite journal</target><arg name="author">Cozzi N.V., Gopalakrishnan A., Anderson L.L., Feih J.T., Shulgin A.T., Daley P.F., Ruoho A.E.<space/></arg><arg name="title">Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter<space/></arg><arg name="journal">Journal of Neural Transmission<space/></arg><arg name="volume">116<space/></arg><arg name="issue">12<space/></arg><arg name="pages">1591–9<space/></arg><arg name="date">December 2009<space/></arg><arg name="pmid"><space/>19756361<space/></arg><arg name="doi"><space/>10.1007/s00702-009-0308-8<space/></arg><arg name="url">http://www.neurophys.wisc.edu/~cozzi/Hallucinogenic%20tryptamines%20as%20SERT%20and%20VMAT2%20substrates.%20%20Cozzi.%20%20J.%20Neural%20Transm.,%20116,%201591-1599%20(2009).pdf<space/></arg><arg name="format">PDF</arg></template></extension></paragraph><paragraph>As with other so-called &quot;classical hallucinogens&quot;,<extension extension_name='ref' name="nida1994"><template><target>cite book</target><arg name="last1">Glennon<space/></arg><arg name="first1">R.A.<space/></arg><arg name="authorlink1"><space/></arg><arg name="editor1-first">G.C.<space/></arg><arg name="editor1-last">Lin<space/></arg><arg name="editor2-first">R.A.<space/></arg><arg name="editor2-last">Glennon<space/></arg><arg name="title">Hallucinogens: An Update<space/></arg><arg name="url">http://crfdl.org:1111/xmlui/bitstream/handle/123456789/288/hallucinogens%20an%20update.pdf<space/></arg><arg name="series">NIDA Research Monograph Series<space/></arg><arg name="volume">146<space/></arg><arg name="year">1994<space/></arg><arg name="publisher">U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse<space/></arg><arg name="location">Rockville, MD<space/></arg><arg name="isbn"><space/></arg><arg name="page">4<space/></arg><arg name="chapter">Classical hallucinogens: an introductory overview</arg></template></extension><space/>a large part of DMT psychedelic effects can be attributed to a<space/><link><target>functionally selective</target></link><space/>activation of the 5-HT<xhtml:sub>2A</xhtml:sub><space/>receptor.<extension extension_name='ref' name="pmid8297216"></extension><extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid17977517"><template><target>cite journal</target><arg name="author">Fantegrossi W.E., Murnane K.S., Reissig C.J.<space/></arg><arg name="title">The behavioral pharmacology of hallucinogens<space/></arg><arg name="journal">Biochemical Pharmacology<space/></arg><arg name="volume">75<space/></arg><arg name="issue">1<space/></arg><arg name="pages">17–33<space/></arg><arg name="date">January 2008<space/></arg><arg name="pmid">17977517<space/></arg><arg name="pmc">2247373<space/></arg><arg name="doi">10.1016/j.bcp.2007.07.018<space/></arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref' name="pmid14761703"><template><target>cite journal</target><arg name="author"><space/>Nichols D.E.<space/></arg><arg name="title"><space/>Hallucinogens<space/></arg><arg name="journal"><space/>Pharmacology & Therapeutics<space/></arg><arg name="volume">101<space/></arg><arg name="issue">2<space/></arg><arg name="pages">131–81<space/></arg><arg name="date">February 2004<space/></arg><arg name="pmid">14761703<space/></arg><arg name="doi">10.1016/j.pharmthera.2003.11.002<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid9875725"><template><target>cite journal</target><arg name="author">Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Bäbler A., Vogel H., Hell D.<space/></arg><arg name="title"><space/>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action<space/></arg><arg name="journal">NeuroReport<space/></arg><arg name="volume">9<space/></arg><arg name="issue">17<space/></arg><arg name="pages">3897–902<space/></arg><arg name="date">December 1998<space/></arg><arg name="pmid">9875725<space/></arg><arg name="doi">10.1097/00001756-199812010-00024<space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="pmid8788488"><template><target>cite journal</target><arg name="author">Strassman R.J.<space/></arg><arg name="title">Human psychopharmacology of N,N-dimethyltryptamine<space/></arg><arg name="journal">Behavioural Brain Research<space/></arg><arg name="volume">73<space/></arg><arg name="issue">1–2<space/></arg><arg name="pages">121–4<space/></arg><arg name="year">1996<space/></arg><arg name="pmid">8788488<space/></arg><arg name="doi">10.1016/0166-4328(96)00081-2<space/></arg><arg name="url">http://crfdl.org:1111/xmlui/bitstream/handle/123456789/373/Beh_Brain_Res_96.pdf<space/></arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref' name="pmid6513725"><template><target>cite journal</target><arg name="author">Glennon R.A., Titeler M., McKenney J.D.<space/></arg><arg name="title">Evidence for 5-HT<sub>2</sub><space/>involvement in the mechanism of action of hallucinogenic agents<space/></arg><arg name="journal">Life Sciences<space/></arg><arg name="volume">35<space/></arg><arg name="issue">25<space/></arg><arg name="pages">2505–11<space/></arg><arg name="date">December 1984<space/></arg><arg name="pmid">6513725<space/></arg><arg name="doi">10.1016/0024-3205(84)90436-3<space/></arg><arg name="url"></arg></template></extension><space/>DMT concentrations eliciting 50% of its maximal effect (half maximal effective concentration =<space/><link><target>EC50</target><part>EC<xhtml:sub>50</xhtml:sub></part></link><space/>or K<xhtml:sub>act</xhtml:sub>) at the human 5-HT<xhtml:sub>2A</xhtml:sub><space/>receptor<space/><italics>in vitro</italics><space/>are in the 0.1180.983 M range.<extension extension_name='ref' name="pmid19881490"></extension><extension extension_name='ref' name="pmid20126400"></extension><extension extension_name='ref' name="pmid9768567"></extension><extension extension_name='ref' name="pmid9023266"><template><target>cite journal</target><arg name="author">Roth B.L., Choudhary M.S., Khan N., Uluer A.Z.<space/></arg><arg name="title">High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine<sub>2A</sub><space/>receptors: evidence in favor of a modified ternary complex model<space/></arg><arg name="journal">Journal of Pharmacology and Experimental Therapeutics<space/></arg><arg name="volume">280<space/></arg><arg name="issue">2<space/></arg><arg name="pages">576–83<space/></arg><arg name="date">February 1997<space/></arg><arg name="pmid">9023266<space/></arg><arg name="doi"><space/></arg><arg name="url">http://jpet.aspetjournals.org/content/280/2/576.full.pdf<space/></arg><arg name="format">PDF</arg></template></extension><space/>This range of values coincides well with the range of concentrations measured in blood and plasma after administration of a fully psychedelic dose (see<space/><link><target>#Pharmacokinetics</target><part>Pharmacokinetics</part></link>).</paragraph><paragraph>As DMT has been shown to have slightly better efficacy (EC<xhtml:sub>50</xhtml:sub>) at human serotonin 2C receptor than at the 2A receptor,<extension extension_name='ref' name="pmid20126400"></extension><extension extension_name='ref' name="pmid9768567"></extension><space/>5-HT<xhtml:sub>2C</xhtml:sub><space/>is also likely implicated in DMT's overall effects.<extension extension_name='ref' name="pmid14761703"></extension><extension extension_name='ref' name="pmid20165943"><template><target>cite journal</target><arg name="author">Canal C.E., Olaghere da Silva U.B., Gresch P.J., Watt E.E., Sanders-Bush E., Airey D.C.<space/></arg><arg name="title">The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen<space/></arg><arg name="journal">Psychopharmacology<space/></arg><arg name="volume">209<space/></arg><arg name="issue">2<space/></arg><arg name="pages">163–74<space/></arg><arg name="date">April 2010<space/></arg><arg name="pmid">20165943<space/></arg><arg name="doi">10.1007/s00213-010-1784-0<space/></arg><arg name="url">http://www.springerlink.com/content/614528n2772tr715/fulltext.pdf<space/></arg><arg name="format">PDF<space/></arg><arg name="pmc">2868321</arg></template></extension><space/>Other receptors, such as 5-HT<xhtml:sub>1A</xhtml:sub><extension extension_name='ref' name="pmid2540505"></extension><extension extension_name='ref' name="pmid14761703"></extension><extension extension_name='ref' name="pmid8788488"></extension><space/><xhtml:sub>1</xhtml:sub>,<extension extension_name='ref' name="pmid19213917"></extension><extension extension_name='ref' name="pmid19278957"><template><target>cite journal</target><arg name="author">Su T.P., Hayashi T., Vaupel D.B.<space/></arg><arg name="title">When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor<space/></arg><arg name="journal">Science Signaling<space/></arg><arg name="volume">2<space/></arg><arg name="issue">61<space/></arg><arg name="pages">pe12<space/></arg><arg name="year">2009<space/></arg><arg name="pmid">19278957<space/></arg><arg name="doi">10.1126/scisignal.261pe12<space/></arg><arg name="url">http://crfdl.org:1111/xmlui/bitstream/handle/123456789/3/Su%20et%20alvScience%20Signaling%202009.pdf<space/></arg><arg name="format">PDF<space/></arg><arg name="pmc">3155724</arg></template></extension><space/>may also play a role.</paragraph><paragraph>In 2009, it was hypothesized that DMT may be an<space/><link><target>endogenous ligand</target></link><space/>for the<space/><xhtml:sub>1</xhtml:sub><space/>receptor.<extension extension_name='ref' name="pmid19213917"></extension><extension extension_name='ref' name="pmid19278957"></extension><space/>The concentration of DMT needed for<space/><xhtml:sub>1</xhtml:sub><space/>activation<space/><italics>in vitro</italics><space/>(50100 M) is similar to the behaviorally active concentration measured in mouse brain of approximately 106 M<space/><extension extension_name='ref' name="pmid6798607"><template><target>cite journal</target><arg name="author">Morinan A., Collier J.G.<space/></arg><arg name="title">Effects of pargyline and SKF-525A on brain N,N-dimethyltryptamine concentrations and hyperactivity in mice<space/></arg><arg name="journal">Psychopharmacology<space/></arg><arg name="volume">75<space/></arg><arg name="issue">2<space/></arg><arg name="pages">179–83<space/></arg><arg name="year">1981<space/></arg><arg name="pmid">6798607<space/></arg><arg name="doi">10.1007/BF00432184<space/></arg><arg name="url"></arg></template></extension><space/>This is minimally 4 orders of magnitude higher than the average concentrations measured in rat brain tissue or human plasma under basal conditions (see<space/><link><target>#Endogenous DMT</target><part>Endogenous DMT</part></link>), so<space/><xhtml:sub>1</xhtml:sub><space/>receptors are likely to be activated only under conditions of high local DMT concentrations. If DMT is stored in synaptic vesicles,<extension extension_name='ref' name="pmid19756361"></extension><space/>such concentrations might occur during vesicular release. To illustrate, while the<space/><italics>average</italics><space/>concentration of serotonin in brain tissue is in the 1.5-4 M range,<extension extension_name='ref' name="pmid20723248"></extension><extension extension_name='ref' name="pmid16146432"></extension><space/>the concentration of serotonin in synaptic vesicles was measured at 270 mM.<extension extension_name='ref' name="pmid11086995"><template><target>cite journal</target><arg name="author">Bruns D., Riedel D., Klingauf J., Jahn R.<space/></arg><arg name="title">Quantal release of serotonin<space/></arg><arg name="journal">Neuron<space/></arg><arg name="volume">28<space/></arg><arg name="issue">1<space/></arg><arg name="pages">205–20<space/></arg><arg name="date">October 2000<space/></arg><arg name="pmid">11086995<space/></arg><arg name="doi">10.1016/S0896-6273(00)00097-0<space/></arg><arg name="url"></arg></template></extension><space/>Following vesicular release, the resulting concentration of serotonin in the synaptic cleft, to which serotonin receptors are exposed, is estimated to be about 300 M. Thus, while<space/><italics>in vitro</italics><space/>receptor binding affinities, efficacies, and average concentrations in tissue or plasma are useful, they are not likely to predict DMT concentrations in the vesicles or at synaptic or intracellular receptors. Under these conditions, notions of receptor selectivity are moot, and it seems probable that most of the receptors identified as targets for DMT (see above) participate in producing its psychedelic effects.</paragraph><table class="wikitable"><tablerow><tablehead>Binding Sites</tablehead><tablehead>Binding Affinity Ki(nm)<extension extension_name='ref'>Ray TS (2010) Psychedelics and the Human Receptorome. PLoS ONE 5(2): e9019. doi:10.1371/journal.pone.0009019</extension></tablehead></tablerow><tablerow><tablecell>5ht1a</tablecell><tablecell>&gt;10,000</tablecell></tablerow><tablerow><tablecell>5ht1b</tablecell><tablecell>&gt;10,000</tablecell></tablerow><tablerow><tablecell>5ht1d</tablecell><tablecell>93</tablecell></tablerow><tablerow><tablecell>5ht1e</tablecell><tablecell>455.7</tablecell></tablerow><tablerow><tablecell>5ht2a</tablecell><tablecell>2323</tablecell></tablerow><tablerow><tablecell>5ht2b</tablecell><tablecell>107.6</tablecell></tablerow><tablerow><tablecell>5ht2c</tablecell><tablecell>334.6</tablecell></tablerow><tablerow><tablecell>5ht5a</tablecell><tablecell>611</tablecell></tablerow><tablerow><tablecell>5ht6</tablecell><tablecell>487.4</tablecell></tablerow><tablerow><tablecell>5ht7</tablecell><tablecell>87.5</tablecell></tablerow><tablerow><tablecell>D1</tablecell><tablecell>271.1</tablecell></tablerow><tablerow><tablecell>1A</tablecell><tablecell>1745</tablecell></tablerow><tablerow><tablecell>1B</tablecell><tablecell>973.7</tablecell></tablerow><tablerow><tablecell>2A</tablecell><tablecell>1561</tablecell></tablerow><tablerow><tablecell>2B</tablecell><tablecell>257.7</tablecell></tablerow><tablerow><tablecell>2C</tablecell><tablecell>258.6</tablecell></tablerow><tablerow><tablecell>SERT</tablecell><tablecell>3742</tablecell></tablerow></table><heading level='2'>As a psychedelic</heading><paragraph><link><target>Image:Dmtlab.jpg</target><part>right</part><part>thumb</part><part>DMT during various stages of purification</part></link>DMT is produced in many species of plants often in conjunction with its close chemical relatives<space/><link><target>5-MeO-DMT</target></link><space/>and<space/><link><target>bufotenin</target></link><space/>(5-OH-DMT).<extension extension_name='ref' name="ISBN 0789026422"></extension><space/>DMT-containing plants are commonly used in South American<space/><link><target>shaman</target><trail>ic</trail></link><space/>practices. It is usually one of the main active constituents of the drink<space/><link><target>ayahuasca</target></link>;<extension extension_name='ref' name="RivierLindgren1972"><template><target>cite journal</target><arg name="last1">Rivier<space/></arg><arg name="first1">Laurent</arg><arg name="last2">Lindgren</arg><arg name="first2">Jan-Erik</arg><arg name="title">'Ayahuasca,' the South American hallucinogenic drink: An ethnobotanical and chemical investigation</arg><arg name="journal">Economic Botany<space/></arg><arg name="volume">26</arg><arg name="issue">2</arg><arg name="year">1972</arg><arg name="pages">101–129</arg><arg name="issn">0013-0001</arg><arg name="doi">10.1007/BF02860772</arg></template></extension><extension extension_name='ref' name="McKennaTowers1984"><template><target>cite journal</target><arg name="last1">McKenna</arg><arg name="first1">Dennis J.</arg><arg name="last2">Towers</arg><arg name="first2">G.H.N.</arg><arg name="last3">Abbott</arg><arg name="first3">F.</arg><arg name="title">Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of Ayahuasca</arg><arg name="journal">Journal of Ethnopharmacology<space/></arg><arg name="volume">10<space/></arg><arg name="issue">2<space/></arg><arg name="year">1984<space/></arg><arg name="pages">195–223<space/></arg><arg name="issn">03788741<space/></arg><arg name="doi">10.1016/0378-8741(84)90003-5<space/></arg><arg name="pmid">6587171</arg></template></extension><space/>however, ayahuasca is sometimes brewed with plants that do not produce DMT. It occurs as the primary psychoactive<space/><link><target>alkaloid</target></link><space/>in several plants including<space/><italics><link><target>Mimosa tenuiflora</target></link></italics>,<space/><italics><link><target>Diplopterys cabrerana</target></link></italics>, and<space/><italics><link><target>Psychotria viridis</target></link></italics>. DMT is found as a minor alkaloid in snuff made from<space/><link><target>Virola</target></link><space/>bark resin in which<space/><link><target>5-MeO-DMT</target></link><space/>is the main active alkaloid.<extension extension_name='ref' name="ISBN 0789026422"></extension><space/>DMT is also found as a minor alkaloid in bark, pods, and beans of<space/><italics><link><target>Anadenanthera peregrina</target></link></italics><space/>and<space/><italics><link><target>Anadenanthera colubrina</target></link></italics><space/>used to make<space/><link><target>Yopo</target></link><space/>and<space/><link><target>Anadenanthera colubrina</target><part>Vilca</part></link><space/>snuff in which<space/><link><target>bufotenin</target></link><space/>is the main active alkaloid.<extension extension_name='ref' name="ISBN 0789026422"><template><target>cite book</target><arg name="title">Anadenanthera: Visionary Plant Of Ancient South America<space/></arg><arg name="last1">Torres<space/></arg><arg name="first1">Constantino Manuel<space/></arg><arg name="last2">Repke<space/></arg><arg name="first2">David B.<space/></arg><arg name="year">2006<space/></arg><arg name="publisher">Haworth Herbal<space/></arg><arg name="location">Binghamton, NY<space/></arg><arg name="isbn">978-0-7890-2642-2<space/></arg><arg name="pages">107–122</arg></template></extension><extension extension_name='ref' name="pmid11718320"><template><target>cite journal</target><arg name="author">Ott J.<space/></arg><arg name="title">Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine<space/></arg><arg name="journal">Journal of Psychoactive Drugs<space/></arg><arg name="volume">33<space/></arg><arg name="issue">3<space/></arg><arg name="pages">273–81<space/></arg><arg name="year">2001<space/></arg><arg name="pmid">11718320<space/></arg><arg name="doi"><space/>10.1080/02791072.2001.10400574</arg><arg name="url">http://files.shroomery.org/attachments/8588382-pharmanopo_J_Ott_2001_J_Psych_Drug.pdf<space/></arg><arg name="format">PDF</arg></template></extension><space/><link><target>Psilocin</target></link>, an active chemical in many<space/><link><target>Psilocybin mushrooms</target><part>psychedelic mushrooms</part></link>, is structurally similar to DMT.</paragraph><paragraph>The psychotropic effects of DMT were first studied scientifically by the<space/><link><target>Hungary</target><part>Hungarian</part></link><space/>chemist and psychologist Dr.<space/><link><target>Stephen Szra</target></link>, who performed research with volunteers in the mid-1950s. Szra, who later worked for the US<space/><link><target>National Institutes of Health</target></link>, had turned his attention to DMT after his order for<space/><link><target>LSD</target></link><space/>from the Swiss company<space/><link><target>Sandoz Laboratories</target></link><space/>was rejected on the grounds that the powerful psychotropic could be dangerous in the hands of a communist country.<extension extension_name='ref' name="strassman"></extension></paragraph><paragraph>DMT can produce powerful<space/><link><target>psychedelic experience</target><trail>s</trail></link><space/>including intense visuals, euphoria and<space/><link><target>hallucinations</target></link>.<extension extension_name='ref' name="DMT_Erowid"><template><target>cite web</target><arg name="url">http://www.erowid.org/chemicals/dmt/dmt.shtml<space/></arg><arg name="title">Erowid DMT (Dimethyltryptamine) Vault<space/></arg><arg name="publisher">Erowid.org<space/></arg><arg name="date"><space/></arg><arg name="accessdate">2012-09-20</arg></template></extension><space/>DMT is generally not active orally unless it is combined with a<space/><link><target>monoamine oxidase inhibitor</target></link><space/>(MAOI) such as a<space/><link><target>reversible inhibitor of monoamine oxidase A</target></link><space/>(RIMA), for example,<space/><link><target>harmaline</target></link>.<extension extension_name='ref' name="pmid6587171"></extension><space/>Without an MAOI, the body quickly metabolizes orally administered DMT, and it therefore has no hallucinogenic effect unless the dose exceeds monoamine oxidase's metabolic capacity. Other means of ingestion such as vaporizing, injecting, or insufflating the drug can produce powerful hallucinations for a short time (usually less than half an hour), as the DMT reaches the brain before it can be metabolized by the body's natural monoamine oxidase. Taking a MAOI prior to vaporizing or injecting DMT prolongs and potentiates the effects.<extension extension_name='ref' name="DMT_Erowid"></extension></paragraph><heading level='3'>&quot;Machine Elves&quot;</heading><paragraph><template><target>anchor</target><arg>Machine elves</arg></template>One common feature of the hallucinogenic experience caused by DMT are hallucinations of humanoid beings, characterised as being otherworldly. The term<space/><italics>Machine Elf</italics><space/>was coined by ethnobotanist<space/><link><target>Terence McKenna</target></link><space/>for the experience, who also used the terms<space/><italics>fractal elves</italics>, or<space/><italics>self-transforming machine elves</italics>.<extension extension_name='ref' name="Dmt: the Spirit Molecule"><template><target>cite book</target><arg name="author"><space/>Rick Strassman<space/></arg><arg name="title">Dmt: the Spirit Molecule: A Doctor's Revolutionary Research into the Biology of near-Death and Mystical Experiences<space/></arg><arg name="year">2001<space/></arg><arg name="isbn"><space/>978-0-89281-927-0</arg><arg name="pages"><space/>187–8, also pp.173–4</arg><arg name="quote">I had expected to hear about some of these types of experiences once we began giving DMT. I was familiar with Terence McKenna's tales of the "self-transforming machine elves" he encountered after smoking high doses of the drug. Interviews conducted with twenty experienced DMT smokers before beginning the New Mexico research also yielded some tales of similar meetings. Since most of these people were from California, I admittedly chalked up these stories to some kind of West Coast eccentricity</arg></template></extension><extension extension_name='ref'><template><target>citation</target><arg name="title"><space/>The Invisible Landscape: Mind, Hallucinogens and the I Ching</arg><arg name="first"><space/>Terence<space/></arg><arg name="last"><space/>McKenna</arg><arg name="year">1975</arg></template></extension></paragraph><paragraph>Hallucinations of strange creatures had been reported by Szara in the<space/><italics>Journal of Mental Science</italics><space/>(now the<space/><link><target>British Journal of Psychiatry</target></link>) (1958)<space/><italics>Dimethyltryptamine Experiments with Psychotics</italics>,<space/><link><target>Stephen Szara</target></link><space/>described how one of his subjects under the influence of DMT had experienced strange creatures, dwarves or something at the beginning of a DMT trip.<extension extension_name='ref'><template><target>citation</target><arg name="url"><space/>http://www.redicecreations.com/article.php?id</arg><arg name="title">Causal Multiplicity: The Science Behind Schizophrenia</arg><arg name="date"><space/>10 September 2010</arg><arg name="first"><space/>Micah A.<space/></arg><arg name="last"><space/>Hanks</arg></template></extension></paragraph><paragraph>Other researchers of the experience described 'entities' or 'beings' in humanoid as well as animal form, with descriptions of &quot;little people&quot; being common (non-human gnomes, elves, imps etc.). This form of hallucination has been speculated to be the cause of<space/><link><target>alien abduction</target></link><space/>experiences through<space/><link><target>endogenous</target><trail>ly</trail></link><space/>occurring DMT.<extension extension_name='ref'><template><target>citation</target><arg name="last"><space/>Luke</arg><arg name="first"><space/>D.</arg><arg name="year"><space/>2011</arg><arg name="title"><space/>Discarnate entities and dimethyltryptamine (DMT): Psychopharmacology, phenomenology and ontology.<space/></arg><arg name="url"><space/>http://www.scribd.com/doc/70007742/Discarnate-Entities<space/></arg><arg name="journal"><space/>Journal of the Society for Psychical Research</arg><arg name="volume"><space/>75</arg><arg name="number"><space/>902</arg><arg name="pages"><space/>26–42</arg></template></extension><extension extension_name='ref'><template><target>citation</target><arg name="last"><space/>Luke</arg><arg name="first"><space/>D. P.<space/></arg><arg name="year">2012</arg><arg name="title"><space/>Psychoactive substances and paranormal phenomena: A comprehensive review.<space/></arg><arg name="url">http://www.transpersonalstudies.org/ImagesRepository/ijts/Downloads/Luke%20IJTS%2031(1)-2012.pdf<space/></arg><arg name="journal"><space/>International Journal of Transpersonal Studies</arg><arg name="volume"><space/>31</arg><arg name="pages"><space/>97–156</arg></template></extension></paragraph><paragraph><link><target>Cliff Pickover</target></link><space/>has also written about the &quot;machine elf&quot;-experience, in the book<space/><italics>Sex, Drugs, Einstein, &amp; Elves</italics>.<extension extension_name='ref'><template><target>cite book</target><arg name="title">Sex, Drugs, Einstein, and Elves: Sushi, Psychedelics, Parallel Universes, and the Quest for Transcendence<space/></arg><arg name="last">Pickover<space/></arg><arg name="first">Cliff<space/></arg><arg name="year">2005<space/></arg><arg name="publisher"><space/>Smart Publications</arg><arg name="isbn">1-890572-17-9</arg></template></extension></paragraph><heading level='2'>Routes of administration</heading><heading level='3'>Inhalation</heading><paragraph><template><target>Refimprove section</target><arg name="date">July 2012</arg></template>A standard dose for vaporized DMT is 1560&amp;nbsp;mg. In general, this is inhaled in a few successive breaths. The effects last for a short period of time, usually 5 to 15 minutes, dependent on the dose. The onset after inhalation is very fast (less than 45 seconds) and peak effects are reached within a minute. In the 1960s, DMT was known as a &quot;businessman's trip&quot; in the US because of the relatively short duration (and rapid onset) of action when inhaled.<extension extension_name='ref'><template><target>cite journal</target><arg name="title">Emerging Drugs of Abuse<space/></arg><arg name="date">November 2005<space/></arg><arg name="last1">Haroz<space/></arg><arg name="first1">Rachel</arg><arg name="last2">Greenberg</arg><arg name="first2">Michael I.<space/></arg><arg name="journal">Medical Clinics of North America<space/></arg><arg name="volume">89<space/></arg><arg name="issue">6<space/></arg><arg name="pages">1259–76<space/></arg><arg name="location">Philadelphia<space/></arg><arg name="publisher">[[Saunders (publisher)|Saunders]]<space/></arg><arg name="issn">0025-7125<space/></arg><arg name="oclc">610327022<space/></arg><arg name="doi">10.1016/j.mcna.2005.06.008<space/></arg><arg name="pmid">16227062<space/></arg><arg name="quote">Use of DMT was first encountered in the United States in the 1960s, when it was known as a 'businessman's trip' because of the rapid onset of action when smoked (2 to 5 minutes) and short duration of action (20 minutes to 1 hour).</arg></template></extension></paragraph><heading level='3'>Injection</heading><paragraph>Injected DMT produces an experience that is similar to inhalation in duration, intensity, and characteristics.</paragraph><paragraph>In a study conducted from 1990 through 1995,<space/><link><target>University of New Mexico</target></link><space/>psychiatrist<space/><link><target>Rick Strassman</target></link><space/>found that some volunteers injected with high doses of DMT reported experiences with perceived<space/><link><target>Extraterrestrial life in culture</target><part>alien</part></link><space/>entities. Usually, the reported entities were experienced as the inhabitants of a perceived independent reality the subjects reported visiting while under the influence of DMT.<extension extension_name='ref' name="strassman"></extension><space/>In a September 2009 interview with Examiner.com, Strassman described the effects on participants in the study: &quot;Subjectively, the most interesting results were that high doses of DMT seemed to allow the consciousness of our volunteers to enter into non-corporeal, free-standing, independent realms of existence inhabited by beings of light who oftentimes were expecting the volunteers, and with whom the volunteers interacted. While 'typical' near-death and mystical states occurred, they were relatively rare.&quot;</paragraph><heading level='3'>Oral ingestion</heading><paragraph>DMT is broken down by the enzyme<space/><link><target>monoamine oxidase</target></link><space/>through a process called<space/><link><target>deamination</target></link>, and is quickly inactivated orally unless combined with a<space/><link><target>monoamine oxidase inhibitor</target></link><space/>(MAOI).<extension extension_name='ref' name="pmid6587171"></extension><space/>The traditional South American beverage<space/><link><target>ayahuasca</target></link>, or yage, is derived by boiling the<space/><link><target>Banisteriopsis caapi</target><part>ayahuasca vine</part></link><space/>(<italics>Banisteriopsis caapi</italics>) with leaves of one or more plants containing DMT, such as<space/><italics><link><target>Psychotria viridis</target></link></italics>,<space/><italics><link><target>Psychotria carthagenensis</target></link></italics>, or<space/><italics><link><target>Diplopterys cabrerana</target></link></italics>.<extension extension_name='ref' name="pmid6587171"></extension><space/>The Ayahuasca vine contains<space/><link><target>harmala alkaloids</target></link>,<extension extension_name='ref' name="pmid9924842"><template><target>cite journal</target><arg name="last1">Callaway<space/></arg><arg name="first1">James C.<space/></arg><arg name="last2">Grob<space/></arg><arg name="first2">Charles S.<space/></arg><arg name="title">Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions<space/></arg><arg name="journal">Journal of Psychoactive Drugs<space/></arg><arg name="volume">30<space/></arg><arg name="issue">4<space/></arg><arg name="pages">367–9<space/></arg><arg name="year">1998<space/></arg><arg name="pmid">9924842<space/></arg><arg name="issn">0279-1072<space/></arg><arg name="doi">10.1080/02791072.1998.10399712<space/></arg><arg name="url">http://www.mimosahostilis.com/files/Ayahuasca%20and%20SSRI%20Interactions.pdf<space/></arg><arg name="format">PDF</arg></template></extension><space/>highly active reversible inihibitors of monoamine oxidase A (<link><target>Reversible inhibitor of monoamine oxidase A</target><part>RIMA</part><trail>s</trail></link>),<extension extension_name='ref' name="BergstrmWesterberg1997"><template><target>cite journal</target><arg name="last1">Bergström</arg><arg name="first1">Mats</arg><arg name="last2">Westerberg</arg><arg name="first2">Göran</arg><arg name="last3">Långström</arg><arg name="first3">Bengt</arg><arg name="title"><sup>11</sup>C-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies</arg><arg name="journal">Nuclear Medicine and Biology</arg><arg name="volume">24</arg><arg name="issue">4</arg><arg name="year">1997</arg><arg name="pages">287–293</arg><arg name="issn">09698051</arg><arg name="doi">10.1016/S0969-8051(97)00013-9</arg><arg name="pmid">9257326</arg></template></extension><space/>rendering the DMT orally active by protecting it from<space/><link><target>deamination</target></link>.<extension extension_name='ref' name="pmid6587171"></extension><space/>A variety of different recipes are used to make the brew depending on the purpose of the ayahuasca session,<extension extension_name='ref' name="Andritzky1989"><template><target>cite journal</target><arg name="last1">Andritzky</arg><arg name="first1">Walter</arg><arg name="title">Sociopsychotherapeutic Functions of Ayahuasca Healing in Amazonia</arg><arg name="journal">Journal of Psychoactive Drugs</arg><arg name="volume">21</arg><arg name="issue">1</arg><arg name="year">1989</arg><arg name="pages">77–89</arg><arg name="issn">0279-1072</arg><arg name="pmid">2656954</arg><arg name="doi">10.1080/02791072.1989.10472145</arg><arg name="accessdate">10 April 2012</arg><arg name="url">http://www.lila.info/document_view.phtml?document_id</arg><arg name="archiveurl">http://web.archive.org/web/20080226052014/http://www.lila.info/document_view.phtml?document_id</arg><arg name="archivedate">26 February 2008</arg><arg name="deadurl">yes</arg></template></extension><space/>or local availability of ingredients. Two common sources of DMT in the western US are<space/><link><target>reed canary grass</target></link><space/>(<italics><link><target>Phalaris arundinacea</target></link></italics>) and<space/><link><target>Harding grass</target></link><space/>(<italics><link><target>Phalaris aquatica</target></link></italics>). These invasive grasses contain low levels of DMT and other alkaloids. In addition,<space/><link><target>Jurema</target></link><space/>(<italics><link><target>Mimosa tenuiflora</target></link></italics>) shows evidence of DMT content: the pink layer in the inner rootbark of this small tree contains a high concentration of<space/><italics>N,N</italics>-DMT.<template><target>citation needed</target><arg name="date">December 2014</arg></template></paragraph><paragraph>Taken orally with an<space/><link><target>Reversible inhibitor of monoamine oxidase A</target><part>RIMA</part></link>, DMT produces a long lasting (over 3 hour), slow, deep metaphysical experience similar to that of<space/><link><target>psilocybin mushrooms</target></link>, but more intense.<extension extension_name='ref' name="Peru"><template><target>cite web</target><arg name="url">http://www.kirasalak.com/Peru.html<space/></arg><arg name="title">Hell and back<space/></arg><arg name="last">Salak<space/></arg><arg name="first">Kira<space/></arg><arg name="publisher">National Geographic Adventure<space/></arg></template></extension><space/><link><target>Reversible inhibitor of monoamine oxidase A</target><part>RIMA</part><trail>s</trail></link><space/>should be used with caution as they can have lethal complications with some prescription drugs such as SSRI antidepressants, and some over-the-counter drugs.<extension extension_name='ref' name="pmid9924842"></extension><space/></paragraph><paragraph>Induced DMT experiences can include profound time-dilation, visual and auditory illusions, and other experiences that, by most firsthand accounts, defy verbal or visual description. Some users report intense erotic imagery and sensations and utilize the drug in a ritual sexual context.<extension extension_name='ref' name="Peru"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.maps.org/news-letters/v12n1/12125set.html<space/></arg><arg name="title">2C-B, DMT, You and Me<space/></arg><arg name="accessdate">2007-01-13<space/></arg><arg name="publisher">Maps</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.miqel.com/entheogens/psychedelics_entheogens.html<space/></arg><arg name="title"><space/>Entheogens & Visionary Medicine Pages<space/></arg><arg name="accessdate">2007-08-17<space/></arg><arg name="publisher">Miqel.com</arg></template></extension></paragraph><heading level='2'>Detection in body fluids</heading><paragraph>DMT may be measured in blood, plasma or urine using chromatographic techniques as a diagnostic tool in clinical poisoning situations or to aid in the medicolegal investigation of suspicious deaths. In general, blood or plasma DMT levels in recreational users of the drug are in the 1030 g/L range during the first several hours post-ingestion.<template><target>Citation needed</target><arg name="reason">Such precise values range needs one or more reliable sources</arg><arg name="date">January 2012</arg></template><space/>Less than 0.1% of an oral dose is eliminated unchanged in the 24-hour urine of humans.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Callaway JC, Raymon LP, Hearn WL Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca<space/></arg><arg name="journal"><space/>J. Anal. Toxicol.<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="pages"><space/>492–497<space/></arg><arg name="year"><space/>1996<space/></arg><arg name="pmid"><space/>8889686<space/></arg><arg name="title"><space/>Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="doi"><space/>10.1093/jat/20.6.492<space/></arg></template></extension><extension extension_name='ref'>R. Baselt,<space/><italics>Disposition of Toxic Drugs and Chemicals in Man</italics>, 9th edition, Biomedical Publications, Seal Beach, CA, 2011, pp. 525526.</extension><template><target>Clarify</target><arg name="date">March 2014</arg><arg name="reason">unclear language, eliminated unchanged?</arg></template></paragraph><heading level='2'>Effects</heading><heading level='3'>Addictive potential</heading><paragraph>A review of studies on ritual users of the DMT-containing brew<space/><link><target>Ayahuasca</target></link><space/>concluded that: &quot;A decoction of DMT and harmala alkaloids used in religious ceremonies has a safety margin comparable to<space/><link><target>codeine</target></link>,<space/><link><target>mescaline</target></link><space/>or<space/><link><target>methadone</target></link>. The dependence potential of oral DMT and the risk of sustained psychological disturbance are minimal.&quot;<space/><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Robert S. Gable</arg><arg name="title">Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids</arg><arg name="journal">Addiction</arg><arg name="volume">102</arg><arg name="issue">1</arg><arg name="year">2007</arg><arg name="pmid">17207120</arg><arg name="doi">10.1111/j.1360-0443.2006.01652.x</arg><arg name="pages">24–34</arg></template></extension></paragraph><heading level='3'>Physical</heading><paragraph>According to a &quot;Dose-response study of<space/><italics>N,N</italics>-dimethyltryptamine in humans&quot; by<space/><link><target>Rick Strassman</target></link>, &quot;Dimethyltryptamine dose slightly elevated blood pressure, heart rate, pupil diameter, and rectal temperature, in addition to elevating blood concentrations of beta-<link><target>endorphin</target></link>,<space/><link><target>corticotropin</target></link>,<space/><link><target>cortisol</target></link>, and<space/><link><target>prolactin</target></link>.<space/><link><target>Growth hormone</target></link><space/>blood levels rose equally in response to all doses of DMT, and<space/><link><target>melatonin</target></link><space/>levels were unaffected.&quot;<extension extension_name='ref' name="pmid8297216"></extension></paragraph><heading level='2'>Conjecture</heading><paragraph>Several speculative and yet untested hypotheses suggest that<space/><link><target>endogenous</target></link><space/>DMT is produced in the<space/><link><target>human brain</target></link><space/>and is involved in certain<space/><link><target>psychology</target><part>psychological</part></link><space/>and<space/><link><target>neurology</target><part>neurological</part></link><space/>states.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.sbs.com.au/news/article/2013/11/08/dmt-drug-produced-our-brain<space/></arg><arg name="title">DMT: The psychedelic drug 'produced in your brain'<space/></arg><arg name="publisher">SBS<space/></arg><arg name="date">8 November 2013<space/></arg><arg name="accessdate">27 March 2014</arg></template></extension><extension extension_name='ref' name="Wallach J V 2009 914"><template><target>cite journal</target><arg name="author">Wallach J V</arg><arg name="title">Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.<space/></arg><arg name="journal">Med Hypotheses.<space/></arg><arg name="volume">72<space/></arg><arg name="issue">1<space/></arg><arg name="pages">91–4<space/></arg><arg name="year">2009<space/></arg><arg name="pmid">18805646</arg><arg name="doi">10.1016/j.mehy.2008.07.052</arg></template></extension><space/>DMT is naturally occurring in small amounts in rat brain, human cerebrospinal fluid, and other tissues of humans and other mammals.<extension extension_name='ref' name="pmid16095048"></extension><extension extension_name='ref' name="pmid289421"></extension><extension extension_name='ref' name="pmid20877"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.npr.org/templates/story/story.php?storyId</arg><arg name="title">The God Chemical: Brain Chemistry And Mysticism<space/></arg><arg name="publisher">NPR<space/></arg><arg name="date"><space/></arg><arg name="accessdate">2012-09-20</arg></template></extension><space/>A biochemical mechanism for this was proposed by the medical researcher J. C. Callaway, who suggested in 1988 that DMT might be connected with visual dream phenomena: brain DMT levels would be periodically elevated to induce visual dreaming and possibly other natural states of mind.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Callaway J<space/></arg><arg name="title">A proposed mechanism for the visions of dream sleep<space/></arg><arg name="journal">Med Hypotheses<space/></arg><arg name="volume">26<space/></arg><arg name="issue">2<space/></arg><arg name="pages">119–24<space/></arg><arg name="year">1988<space/></arg><arg name="pmid">3412201<space/></arg><arg name="doi">10.1016/0306-9877(88)90064-3</arg></template></extension><space/>A role of endogenous hallucinogens including DMT in higher level sensory processing and awareness was proposed by J. V. Wallach based on a hypothetical role of DMT as a neurotransmitter.<extension extension_name='ref' name="Wallach J V 2009 914"></extension></paragraph><paragraph>Dr.<space/><link><target>Rick Strassman</target></link>, while conducting DMT research in the 1990s at the<space/><link><target>University of New Mexico</target></link>, advanced the controversial hypothesis that a massive release of DMT from the<space/><link><target>pineal gland</target></link><space/>prior to death or near death was the cause of the<space/><link><target>near death experience</target></link><space/>(NDE) phenomenon. Several of his test subjects reported audio or visual hallucinations. His explanation for this was the possible lack of panic involved in the clinical setting and possible dosage differences between those administered and those encountered in actual NDE cases. Several subjects also reported contact with &quot;other beings&quot;, alien like, insectoid or reptilian in nature, in highly advanced technological environments<extension extension_name='ref' name="strassman"></extension><space/>where the subjects were &quot;carried&quot;, &quot;probed&quot;, &quot;tested&quot;, &quot;manipulated&quot;, &quot;dismembered&quot;, &quot;taught&quot;, &quot;loved&quot; and &quot;raped&quot; by these &quot;beings&quot;. Basing his reasoning on his belief that all the enzymatic material needed to produce DMT is found in the pineal gland, and moreover in substantially greater concentrations than in any other part of the body, Strassman has speculated that DMT is made in the<space/><link><target>pineal gland</target></link>(<extension extension_name='ref' name="strassman"></extension><space/>p.&amp;nbsp;69) .</paragraph><paragraph>In the 1950s, the endogenous production of psychoactive agents was considered to be a potential explanation for the hallucinatory symptoms of some psychiatric diseases; this is known as the transmethylation hypothesis.<extension extension_name='ref' name="pmid13152519"><template><target>cite journal</target><arg name="author">Hoffer A., Osmond H., Smythies J.<space/></arg><arg name="title">Schizophrenia; a new approach. II. Result of a year's research<space/></arg><arg name="journal">Journal of Mental Science<space/></arg><arg name="volume">100<space/></arg><arg name="issue">418<space/></arg><arg name="pages">29–45<space/></arg><arg name="date">January 1954<space/></arg><arg name="pmid">13152519<space/></arg><arg name="doi">10.1192/bjp.100.418.29<space/></arg><arg name="url"></arg><arg name="last2">Osmond<space/></arg><arg name="last3">Smythies<space/></arg></template></extension></paragraph><paragraph>In 2011, Nicholas V. Cozzi, of the<space/><link><target>University of Wisconsin School of Medicine and Public Health</target></link>, concluded that<space/><link><target>INMT</target></link>, an enzyme that may be associated with the biosynthesis of DMT and endogenous hallucinogens, is present in the primate (rhesus macaque) pineal gland, retinal ganglion neurons, and spinal cord.<extension extension_name='ref' name="Cozzi N.V., Mavlyutov T.A., Thompson M.A., Ruoho A.E. 2011 840.19"></extension></paragraph><heading level='2'>Legal status</heading><heading level='3'>International law</heading><paragraph>DMT is classified as a Schedule I drug under the<space/><link><target>United Nations</target><part>UN</part></link><space/>1971<space/><link><target>Convention on Psychotropic Substances</target></link>, meaning that use of DMT is supposed to be restricted to scientific research and medical use and international trade in DMT is supposed to be closely monitored. Natural materials containing DMT, including ayahuasca, are explicitly not regulated under the 1971 Psychotropic Convention.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.erowid.org/chemicals/ayahuasca/images/archive/ayahuasca_law_undcp_fax1.jpg<space/></arg><arg name="title">International control of the preparation "ayahuasca"<space/></arg><arg name="first">Herbert<space/></arg><arg name="last">Schaepe<space/></arg><arg name="date"><space/></arg><arg name="month"><space/></arg><arg name="year">2001<space/></arg><arg name="work">Erowid<space/></arg><arg name="format">JPG<space/></arg><arg name="accessdate">November 29, 2010</arg></template></extension></paragraph><heading level='3'>By country</heading><heading level='4'>Australia</heading><paragraph>Between 2011 and 2012, the<space/><link><target>Australian Federal Government</target></link><space/>was considering changes to the<space/><link><target>Criminal law of Australia</target><part>Australian Criminal Code</part></link><space/>that would classify any plants containing any amount of DMT as &quot;controlled plants&quot;.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Consultation on implementation of model drug schedules for Commonwealth serious drug offenses<space/></arg><arg name="url">http://www.ag.gov.au/www/agd/agd.nsf/Page/Consultationsreformsandreviews_ConsultationonimplementationofmodeldrugschedulesforCommonwealthseriousdrugoffences<space/></arg><arg name="date">24 June 2010<space/></arg><arg name="publisher">[[Attorney-General's Department (Australia)|Australian Government, Attorney-General’s Department]]</arg></template></extension><space/>DMT itself was already controlled under current laws. The proposed changes included other similar blanket bans for other substances, such as a ban on any and all plants containing Mescaline or Ephedrine. The proposal was not pursued after political embarrassment on realisation that this would make the official<space/><link><target>List of Australian floral emblems</target><part>Floral Emblem of Australia</part></link>,<space/><link><target>Acacia pycnantha</target></link><space/>(Golden Wattle), illegal. The Therapeutic Goods Administration and federal authority had considered a motion to ban the same, but this was withdrawn in May 2012 (as DMT may still hold potential entheogenic value to native and/or religious people).<extension extension_name='ref'><template><target>cite journal</target><arg name="title"><space/>AUSSIE DMT BAN<space/></arg><arg name="url"><space/>http://connection.ebscohost.com/c/articles/79564875/aussie-dmt-ban<space/></arg><arg name="date"><space/>August 2012<space/></arg><arg name="journal"><space/>American Herb Association Quarterly Newsletter<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>14</arg></template></extension></paragraph><heading level='4'>Canada</heading><paragraph>DMT is classified in<space/><link><target>Canada</target></link><space/>as a<space/><link><target>Controlled Drugs and Substances Act</target><part>Schedule III</part></link><space/>drug under the Controlled Drugs and Substances Act.</paragraph><heading level='4'>France</heading><paragraph>DMT, along with most of its plant sources, is classified in<space/><link><target>France</target></link><space/>as a<space/><italics>stupfiant</italics><space/>(<link><target>narcotic</target></link>).</paragraph><heading level='4'>New Zealand</heading><paragraph>DMT is classified in New Zealand as a Class A drug under the<space/><link><target>Misuse of Drugs Act 1975</target></link>.<extension extension_name='ref'><template><target>cite news</target><arg name="title">Rare drug bound for Blenheim<space/></arg><arg name="first">Michael<space/></arg><arg name="last">Berry<space/></arg><arg name="authorlink2">New Zealand Press Association<space/></arg><arg name="author2">NZPA<space/></arg><arg name="url">http://www.stuff.co.nz/marlborough-express/news/5025678/Rare-drug-bound-for-Blenheim<space/></arg><arg name="newspaper">Malborough Express<space/></arg><arg name="publisher">[[Fairfax New Zealand]]<space/></arg><arg name="location">[[Blenheim, New Zealand|Blenheim]], New Zealand<space/></arg><arg name="date">19 May 2011<space/></arg><arg name="accessdate">23 May 2012</arg></template></extension><extension extension_name='ref' name="NZMoDA"><template><target>cite web</target><arg name="url">http://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436576.html</arg><arg name="title">Schedule 1: Class A controlled drugs</arg><arg name="date">1 May 2012</arg><arg name="work">Misuse of Drugs Act 1975</arg><arg name="publisher">[[Parliamentary Counsel Office (New Zealand)|Parliamentary Counsel Office/Te Tari Tohutohu Pāremata]]</arg><arg name="location">[[Wellington]], N.Z.</arg><arg name="accessdate">23 May 2012</arg><arg name="ref">NZMoDA</arg></template></extension></paragraph><heading level='4'>United Kingdom</heading><paragraph>DMT is classified in the<space/><link><target>United Kingdom</target></link><space/>as a<space/><link><target>Misuse of Drugs Act 1971</target><part>Class A drug</part></link>.</paragraph><heading level='4'>United States</heading><paragraph>DMT is classified in the<space/><link><target>United States</target></link><space/>as a<space/><link><target>List of Schedule I drugs (US)</target><part>Schedule I</part></link><space/>drug under the<space/><link><target>Controlled Substances Act</target><part>Controlled Substances Act of 1970</part></link>.</paragraph><paragraph>In December 2004, the<space/><link><target>Supreme Court of the United States</target><part>Supreme Court</part></link><space/>lifted a stay, thereby allowing the<space/><link><target>Brazil</target></link>-based<space/><link><target>Unio do Vegetal</target></link><space/>(UDV) church to use a decoction containing DMT in their Christmas services that year. This decoction is a tea made from boiled leaves and vines, known as<space/><link><target>hoasca</target></link><space/>within the UDV, and<space/><link><target>ayahuasca</target></link><space/>in different cultures. In<space/><italics><link><target>Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal</target></link></italics>, the Supreme Court heard arguments on November 1, 2005, and unanimously ruled in February 2006 that the U.S. federal government must allow the UDV to import and consume the tea for religious ceremonies under the 1993<space/><link><target>Religious Freedom Restoration Act</target></link>.</paragraph><paragraph>In September 2008, the three<space/><link><target>Santo Daime</target></link><space/>churches filed suit in federal court to gain legal status to import DMT-containing<space/><link><target>ayahuasca</target></link><space/>tea. The case,<space/><italics>Church of the Holy Light of the Queen v. Mukasey</italics>,<extension extension_name='ref'><link type='external' href='http://csp.org/society/docs/SantoDaimeAshland20090318.pdf'>Church of the Holy Light of the Queen v. Mukasey</link></extension><space/>presided over by Judge<space/><link><target>Owen M. Panner</target></link>, was ruled in favor of the Santo Daime church. As of March 21, 2009, a federal judge says members of the church in<space/><link><target>Ashland, Oregon</target><part>Ashland</part></link><space/>can import, distribute and brew ayahuasca. U.S. District Judge<space/><link><target>Owen Panner</target></link><space/>issued a permanent injunction barring the government from prohibiting or penalizing the sacramental use of &quot;Daime tea&quot;. Panner's order said activities of The Church of the Holy Light of the Queen are legal and protected under<space/><link><target>freedom of religion</target></link>. His order prohibits the federal government from interfering with and prosecuting church members who follow a list of regulations set out in his order.<extension extension_name='ref'><template><target>cite court</target><arg name="litigants">Church of the Holy Light of the Queen v. Mukasey<space/></arg><arg name="vol"><space/></arg><arg name="reporter"><space/></arg><arg name="opinion"><space/></arg><arg name="pinpoint"><space/></arg><arg name="court">D. Ore.<space/></arg><arg name="date">2009<space/></arg><arg name="url">http://www.bialabate.net/wp-content/uploads/2009/04/161-31909-permanent-injunction.pdf<space/></arg><arg name="quote">permanently enjoins Defendants from prohibiting or penalizing the sacramental use of Daime tea by Plaintiffs during Plaintiffs' religious ceremonies</arg></template></extension></paragraph><heading level='2'>See also</heading><paragraph><template><target>multicol</target></template></paragraph><list type='bullet'><listitem><link><target>5-MeO-DMT</target></link></listitem><listitem><link><target>Ayahuasca</target></link></listitem><listitem><link><target>Bufotenin</target></link></listitem><listitem><link><target>DMT-N-oxide</target></link></listitem><listitem><link><target>Lysergic acid diethylamide</target><part>LSD</part></link></listitem></list><paragraph><template><target>multicol-break</target></template></paragraph><list type='bullet'><listitem><link><target>Near-death experience</target></link></listitem><listitem><link><target>Pineal gland</target></link></listitem><listitem><link><target>Psilocin</target></link></listitem><listitem><link><target>Psychedelic experience</target></link></listitem><listitem><link><target>Serotonergic psychedelic</target></link></listitem></list><paragraph><template><target>multicol-break</target></template></paragraph><list type='def'><listitem><defkey>People</defkey></listitem></list><list type='bullet'><listitem><link><target>Terence McKenna</target></link></listitem><listitem><link><target>Jonathan Ott</target></link></listitem><listitem><link><target>Joe Rogan</target></link></listitem><listitem><link><target>Alexander Shulgin</target></link></listitem><listitem><link><target>Rick Strassman</target></link></listitem><listitem><link><target>Adam Kokesh</target></link></listitem></list><paragraph><template><target>multicol-end</target></template></paragraph><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>30em</arg></template></paragraph><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://www.neuroquantology.com/index.php/journal/article/view/410'>Identifying Spiritual Content in First-Person Reports from Ayahuasca Sessions</link></listitem><listitem><link type='external' href='http://www.erowid.org/chemicals/dmt/'>DMT Vault</link><space/><link><target>Erowid</target></link></listitem><listitem><link type='external' href='http://www.thesite.org/drinkanddrugs/drugsafety/drugsatoz/dmt'>DMT</link><space/>TheSite.org</listitem><listitem><link type='external' href='http://www.erowid.org/library/books_online/tihkal/tihkal06.shtml'>DMT chapter from ''TiHKAL''</link></listitem><listitem><link type='external' href='http://www.rickstrassman.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=54&amp;amp;Itemid=54'>''DMT: The Spirit Molecule''</link>, an overview by its author,<space/><link><target>Rick Strassman</target></link></listitem><listitem><template><target>IMDb title</target><arg>1340425</arg><arg>DMT: The Spirit Molecule</arg></template></listitem><listitem><link type='external' href='http://www.vice.com/read/dmt-you-cannot-imagine-a-stranger-drug-or-a-stranger-experience-365'>DMT: You Cannot Imagine a Stranger Drug or a Stranger Experience</link>, an essay on DMT at<space/><link><target>Vice</target></link></listitem><listitem><link type='external' href='http://www.crfdl.org'>CRFDL</link>, a database of scientific research on psychedelics</listitem></list><paragraph><template><target>Hallucinogens</target></template><template><target>Neurotransmitters</target></template><template><target>Serotonergics</target></template><template><target>Sigmaergics</target></template><template><target>Tryptamines</target></template></paragraph><paragraph><template><target>DEFAULTSORT:Dimethyltryptamine</target></template><link><target>Category:Ayahuasca</target></link><link><target>Category:Entheogens</target></link><link><target>Category:Tryptamine alkaloids</target></link><link><target>Category:Psychedelic tryptamines</target></link><link><target>Category:Serotonin receptor agonists</target></link><link><target>Category:Psychedelics, dissociatives and deliriants</target></link></paragraph></article>